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This thesis is about endosonography in pulmonary diseases and consists of two parts. The 
first part focuses on endosonography in the diagnosis of sarcoidosis. The second part includes 
research on the safety profile of the technique. 
PArt I: endosonogrAPhy In the dIAgnosIs of sArCoIdosIs
Background of sarcoidosis
Sarcoidosis is a systemic disease that was first described in 1878 by Jonathan Hutchinson1 that 
also became known as the disease of Besnier and Boeck, named after two pioneering physicians 
of the late 19th century.2,3 Sarcoidosis mostly affects young adults between the age of 20 and 
40 though the disease may present at any age. The disease is characterized by the formation of 
non-caseating granulomas (see image) and can affect virtually every organ, but most commonly 
affects the lungs and intrathoracic lymph nodes. 
The exact pathogenesis of the disease remains unknown. Despite years of research, the 
stimulus that triggers the initial CD4+ T cell alveolitis, followed by the development of non-
caseating granulomas is unclear. Possible etiologies include fine dust4, infectious agents5 and 
there also appears to be a genetic susceptibility.6 
By generalized tissue accumulation of granulomas, sarcoidosis can cause a variety of symp-
toms of which fatigue and cough are among the most prevalent.7 The course of the disease is 
variable, ranging from self-limiting complaints to progression to a chronic disease with severe 
symptoms resulting in death (mortality rate <5%) due to pulmonary fibrosis, cor pulmonale 
or cardiac arrhythmia.8 Therapy, indicated for those patients with severe organ dysfunction, 
includes high dose glucocorticoids or other immunosuppressive agents. 
The incidence of sarcoidosis varies between 1 to 40 per 100.000 population, depending on 
race and age. The disease is most prevalent in those of (northern) European and African de-
scent, but rare in Asian, Native American and Inuit people.9 In the Netherlands, the estimated 
annual incidence of sarcoidosis is 2000 patients.10 The true prevalence of sarcoidosis is expected 
to be higher as sarcoidosis often manifests itself subclinical. Data from a historical cohort of 
more than a million US Navy recruits showed that almost 50% of patients with sarcoidosis 
were asymptomatic.11
diagnosing sarcoidosis
There is often a great variance in the severity of symptoms in patients with sarcoidosis. Present-
ing symptoms include exhausting fatigue, cough, dyspnea on exertion, weight loss or night 
sweats, but many patients have no complaints at all and the diagnosis is made because of 
abnormalities found on routine x-ray or CT scan of the chest. 
Generally, experts8,12,13 state that patients with a suspicion of sarcoidosis should undergo a 
step-wise diagnostic approach. This includes a clinical and radiological suspicion of the disease, 
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a tissue confirmation of disease-specific noncaseating granulomas (Figure 1) and a follow-
up period of six months in order to exclude similar presenting diseases such as tuberculosis, 
lymphoma and lung cancer. Patients who present with a combination of symptoms pathog-
nomonic for sarcoidosis including Lofgren syndrome (erythema nodosum, bihilar lymphade-
nopathy, migratory polyarthralgia and fever) are exempted from tissue confirmation. In those 
specific cases a clinical/radiological diagnosis can be made without tissue confirmation. Also, 
in patients with Heerfordt’s syndrome (uveoparotid fever) and asymptomatic bilateral hilar 
lymphadenopathy tissue confirmation of noncaseating granulomas is also often omitted. 
Generally, whether to proceed to invasive diagnostic procedures depends on a lot of factors 
including patient and doctor preference, likelihood of an alternative similar presenting disease 
(e.g. lung cancer or tuberculosis) and the need for treatment with immunosuppressive agents.
Imaging techniques
Once the diagnosis of sarcoidosis is suspected, radiological imaging is the first step to screen for 
involved organs or to select a potential biopsy site. 
figure 1. Cytology aspirate of a non-caseating granuloma as observed in a patient with sarcoidosis
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Staging of pulmonary sarcoidosis is based on chest X-ray scanning: Stage I is defi ned by the 
presence of bihilar lymphadenopathy, stage II includes lymphadenopathy with parenchymal 
disease, in stage III there is only parenchymal disease and stage IV is characterized by fi brosis 
(Figure 2).14 Chest X-ray scanning is widely available but has obvious imitations in image 
resolution. 
Computed tomography (CT) off ers detailed anatomical information of the lungs and 
mediastinum. In sarcoidosis, a chest CT scan can detect specifi c radiological features such 
as diff use mediastinal lymphadenopathy (Figure 3), miliary and fi sural nodules, ground glass 
opacities or alveolar opacities with satellite nodules (“galaxy sign”) but these clues can also be 
observed in a number of other conditions, including infections, neoplasms and occupational 
disorders (silicosis, chronic beryllium disease)15 making them not very specifi c for a diagnosis 
of sarcoidosis. 
Positron emission tomography (PET) is a whole body technique of functional processes in 
the body. When a nuclear tracer is labelled to fl uorodeoxyglucose (FDG) - a glucose analogue - 
and subsequently injected in the body, there will be uptake of FDG in biologically active body 
cells (such as in the cells that form the granulomas). Th e biologically active cells can be visual-
ized in a three-dimensional functional image. In patients with sarcoidosis, PET has proven 
figure 2. Chest X-ray images with sarcoidosis stage I-IV.
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valuable in selecting potential sites for diagnostic biopsy16 and it can be used as an marker of 
disease activity17 but there are no disease-specific PET patterns in pulmonary sarcoidosis. 
Although CT and or PET-CT imaging is helpful in the diagnostic workup of sarcoidosis, 
tissue sampling is often indicated to secure a final diagnosis, especially to rule out lymphoma, 
lung cancer or tuberculosis. 
Bronchoscopic methods 
The vast majority of sarcoidosis patients present with pulmonary, ocular and/or skin manifesta-
tions7 When present, accessible lesions like peripheral lymph nodes and skin lesions should 
be considered first if tissue sampling is indicated.8 But as these sites are infrequently involved, 
sampling of the lungs and/or intrathoracic lymph nodes is usually the next best option as >85% 
of sarcoidosis patients have pulmonary or mediastinal involvement.7
Various endoscopic techniques are available to obtain tissue to demonstrate granulomas.
Peripheral lung biopsy (TBLB)
TBLB is one of the most commonly used bronchoscopic biopsy techniques in the diagnostic 
workup of sarcoidosis.However, the technique has a modest average yield (59%) of which the 
reported range is also variable (32%-100%).18 Many factors are thought to contribute to the 
variance in yield. It may be a matter of patient selection as the accuracy of TBLB for higher 
stages of sarcoidosis is better.18 Also experience with the procedure or the use of fluoroscopy 
may influence sensitivity in the assessment of granulomas. Moreover, the yield in trials can be 
somewhat optimistic due to a protocol-guided taking of a minimum number of biopsies. It has 
been demonstrated that at least 6 biopsies are required for stage II sarcoidosis and 8-10 in stage 
I to obtain the optimal yield.19,20 Investigators often refrain from performing this amount of 
biopsies because of fear of severe adverse events (SAE). Generally TBLB is associated with a rate 
figure 3. Computed tomography 
(CT) scan of the thorax displaying 
the heart and great vessels, the lungs 
and multiple enlarged mediastinal 
and hilar lymph nodes.
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of SAE of 3.1% including pneumothorax (2.3%; of which 1% requiring tube thoracostomy), 
bleeding of 40-100 ml (0.6%) and pneumomediastinum (0.2%).18
Endobronchial mucosa biopsies (EBB)
Endobronchial biopsy (EBB) on its own has modest value in diagnosing sarcoidosis with yields 
ranging from 11-49%.21-24 Nevertheless, the risk of complications is minimal and it is good 
to recognize that EBB might be of value in case visible mucosal abnormalities are present and 
granulomas may be found in 54-91%. Also in normal appearing mucosa, granulomas may be 
found in 20-40%.18
Conventional transbronchial needle aspiration (cTBNA)
Transbronchial needle aspiration (TBNA) of mediastinal lymph nodes (Figure 4) was initially 
described in 1949 by Argentinian thoracic surgeon E. Schieppati when he punctured a sub-
carinal mass using rigid bronchoscopy.25 Th e invention of the fl exible bronchoscope in 1966 
by dr. Ikeda further advanced diagnostic bronchoscopy, as did the development of improved 
optics and light sources. With TBNA, specifi cally the right-sided paratracheal lymph node 
stations 4R and the subcarinal station 7, as defi ned by the TNM system26, are accessible to 
“conventional” transbronchial aspiration. Because of the ease of the procedure, low cost and 
low complication rate, TBNA is often posed as the initial procedure to assess granulomas 
in patients with generalized mediastinal lymphadenopathy but also to diagnose lung cancer, 
tuberculosis or lymphoma. Th e outcome of conventional TBNA in sarcoidosis, however is 
highly variable with a yield of 6-90% as shown by a recent meta-analysis (pooled effi  cacy 62%) 
and thus a large number of patients remain non-diagnostic after cTBNA.18
figure 4. Regional lymph node stations adapted 





Several experts suggest that bronchoalveolar lavage (BAL) should be performed in all patients 
suspected of having sarcoidosis as it contributes to the diagnosis process12,13,27
BAL determines lymphocyte subsets including the CD4/CD8 ratio, which may contribute 
to the diagnosis of sarcoidosis. By counting the CD4 en CD8 positive T-lymphocytes, a CD4/
CD8 ratio may be calculated. A CD4/CD8 ratio > 3.5 has been reported to correspond with a 
high positive predictive value (PPV) (94%) for sarcoidosis and other interstitial lung diseases 
(ILD). However, the lavage fluid does not revenue the granulomas required for a diagnosis of 
sarcoidosis and with a PPV of only 50% the CD4/CD8 ratio has minimal value to distinguish 
sarcoidosis from non-ILDs such as lymphoma and lung cancer.28
Surgical biopsy
In some cases where endoscopic techniques do not provide a classifying diagnosis, surgery is 
performed as the next step.
Mediastinoscopy is a type of “key-hole surgery” in which the left and right paratracheal 
and subcarinal areas are biopsied. With a similar procedure called “extended mediastinoscopy” 
the aortopulmonary window (stations 5 and 6) and subcarinal station (station 7) may also 
be reached for tissue evaluation. By extracting lymph nodes with video-assisted mediastinal 
lymphadenectomy sensitivities of 90-100% may be obtained.29,30 However, mediastinoscopy 
also has its downsides: Amongst others, it requires general anaesthesia, a hospital stay and in-
creased expenses and it has a relatively high morbidity rate (1%) including recurrent laryngeal 
nerve injury, haemorrhage, tracheal injury and pneumothorax.31
endosonography
In 1991 Danish surgeon Peter Vilmann first applied a tool that was capable of visualizing 
mediastinal nodes and sample them under real-time sonographic guidance. He used a modified 
gastroscope with a linear ultrasonic head attached, allowing visualization of the mediastinal 
lesions in direct proximity to the esophagus.32 By 1996, endoscopic ultrasound (EUS) had 
been established as an alternative method to CT for evaluating cancers in the upper GI tract. 
After a working channel was incorporated in the scope it was possible to sample mediastinal 
masses, but also lymph nodes as small as 4 mm under real-time sonographic guidance.33,34 
Pulmonologists started to use the oesophagus as an approach route to diagnose mediastinal or 
centrally located pulmonary lesions, located adjacent to the oesophageal wall. 
Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) provides access to the 
lower mediastinum, home to lymph node stations 7, 8 and 9. Nodes in the aortapulmonary 
window (5 and 6) can be easily visualized but often sampling is difficult due to intervening 
vascular structures. Lymph nodes stations in direct proximity to the large airways are out of 
reach of EUS-FNA because of air interfering with the ultrasound signals. 
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In 2000 Fritscher Ravens was the first to report on EUS-FNA in investigating patients with 
sarcoidosis.35
It took some time to develop a sonographic head small enough to be fitted on the smaller 
bronchoscope and in 2003 Krasnik first described real-time endobronchial ultrasound-guided 
transbronchial needle aspiration (EBUS-TBNA).36 EBUS visualizes and samples the regions in 
the mediastinum adjacent to the large airways. The reach of EBUS-TBNA overlaps with that 
of mediastinoscopy and it is complimentary to that of EUS-FNA.37 Both an EUS and EBUS 
investigation including multiple nodal samplings can be performed in an ambulatory setting 
in around 20 minutes, usually under conscious sedation.
In preliminary retrospective studies it had been shown that the detection rate of noncaseating 
granulomas for endosonography (EUS and EBUS) was approximately 80% with few adverse 
events.38-41 This high granuloma detection rate – superior to that reported for traditional 
bronchoscopic sampling methods – resulted in the wish to compare endosonography to the 
standard bronchoscopic methods. 
PArt II: sAfety of endosonogrAPhy
When novel interventional techniques are introduced and implemented in routine clinical 
practice, safety issues are important. EUS-FNA and EBUS-TBNA were introduced in The 
Netherlands in the Leiden University Medical Center in 1999 and 2004 respectively, and 
are now widely available throughout the country. Mostly, literature on endosonography has 
focused largely on the feasibility and yield of the technique. Case reports have been reported 
regarding (serious) adverse events, mainly cautioning against the aspiration of mediastinal cysts 
and necrotic lymph nodes as increased rates of infections were observed following FNA.42,43 
Further, small retrospective (44) and prospective studies (45, 46) were published, describing 
low numbers of serious adverse events and no mortality. Although the safety profile seemed 
favourable, data outside of clinical trials or expert centres were limited.
AIms of the thesIs 
Part I – endosonography in the diagnosis of sarcoidosis
At the initiation of our research, conventional bronchoscopy was regarded the first line-
technique for tissue sampling in case of suspected pulmonary sarcoidosis, despite a moderate 
overall yield in the assessment of granulomas. The position of endosonography (EUS/EBUS) 
with intrathoracic lymph node sampling vs. the use of conventional bronchoscopy techniques 
in the workup of sarcoidosis was unknown. Within the pulmonary community, the optimal 
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strategy to provide tissue proof of noncaseating granulomas in a patient suspected of having 
sarcoidosis was often subject of debate. 
Hence our primary aim was to:
Compare endosonography (EBUS/ EUS) including intrathoracic nodal sampling with con-
ventional bronchoscopy with transbronchial and endobronchial biopsy for the diagnosis of 
pulmonary sarcoidosis stage I/ II
Our secondary aims were to:
- Determine whether there exists a difference in diagnostic yield between stage I and II 
sarcoidosis for both endosonography and conventional bronchoscopy. 
- Determine the specificity of the bronchoalveolar lavage in the diagnosis of sarcoidosis and 
investigate whether a positive BAL obviates the need for (more invasive) tissue sampling.
- Assess safety and serious adverse events of endosonography in de diagnosis of sarcoidosis.
Part II – safety of endosonography
Our aims in this part on the safety of endosonography were to:
- Assess morbidity and mortality rates of EUS and EBUS in pulmonary medicine in the 
literature and throughout the Netherlands
- To identify certain risk factors for complications or subsets of patients at risk of developing 
serious adverse events.
General introduction and aims of the thesis
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outlIne of the thesIs
Chapter 2 describes a retrospective analysis of all patients who were referred for EUS-FNA 
for a suspicion of pulmonary sarcoidosis in the period 2004-2009 in the Leiden University 
Medical Center. Besides diagnostic yield, we focussed on pathology handling, specifically on 
the additional value of cell-block analysis to conventional cytological smears.
Results from this paper have led to initiation of a multi-center randomized clinical trial in 14 
centers in 6 countries, described in Chapter 3 in which the diagnostic yield of endosonography 
(EUS and EBUS) to detect non-caseating granulomas in patients with a final diagnosis of sar-
coidosis was compared to conventional bronchoscopy (TBLB and EBB). Secondary outcome 
measurements were the complication rates in both study arms as well as the additional value 
of a bronchoalveolar lavage (BAL). A specific serious adverse event of EUS-FNA in sarcoidosis 
patients is addressed in Chapter 4 in where we outline the possibility of mediastinal infections 
following aspiration of sarcoid lymph nodes in a large retrospective cohort of patients in two 
Dutch hospitals. Chapter 5 contains a systematic review of the literature of endosonography-
associated complications. We aimed to assess the rate of serious adverse events and to evaluate 
specific associated risk factors in 16.181 patients. Subsequently, we addressed this issue by 
gathering original data in Chapter 6 in where we quantified the morbidity and mortality of 
endosonography by conducting a retrospective nationwide survey in all Dutch hospitals. .
Chapter 7 describes a case of a serious adverse event of mediastinal-oesophageal fistulae 
following EUS-FNA of a subcarinal node in a patient with tuberculosis. Finally, an unconven-
tional approach to sample lymph nodes in the aortopulmonary window by transaortic needle 
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Background and study aims
Transesophageal endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) of medi-
astinal lymph nodes is increasingly used to detect noncaseating granulomas in patients with 
suspected sarcoidosis. The optimal needle size and tissue processing method for detecting non-
caseating granulomas are debated. We assessed the value of cell-block analysis when added to 
conventional cytological evaluation of EUS aspirates obtained by 22-gauge needles in patients 
with stage I and II sarcoidosis.
Patients and methods
Data from 101 consecutive patients (55 % of whom had previously had a nondiagnostic bron-
choscopy) with suspected pulmonary sarcoidosis (stage I and II), who underwent EUS-FNA of 
mediastinal lymph nodes with 22-gauge needles were retrospectively analyzed.
Results 
The sensitivity of EUS in detecting granulomas was 87 % (cytology and cell-block analysis to-
gether) (stage I, 92 %; stage II, 77 %). In 33 % of cytology negative patients (n = 6), granulomas 
were present in the cell block. The optimal yield for granuloma detection was reached with four 
needle passes. One patient developed mediastinitis after EUS-FNA.
Conclusions
Cell-block analysis added to conventional cytological evaluation of 22-gauge EUS aspirates, re-
sults in a high yield in detecting granulomas in patients with suspected sarcoidosis and reduces 
the false-negative rate substantially. EUS has a considerably higher yield in stage I compared 
with stage II sarcoidosis. For an optimal yield, four needle passes are required.
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IntroduCtIon
Sarcoidosis is a multiorgan disease of unknown etiology which mostly affects young males and 
females and presents with pulmonary involvement in approximately 90 % and with intratho-
racic lymphadenopathy in 85 % of patients.1,2
The diagnosis of sarcoidosis is based on clinical and radiological suspicion, tissue confir-
mation of noncaseating granulomas and exclusion of similarly presenting diseases such as 
tuberculosis, lymphoma, and lung cancer. In the absence of granulomateous lesions in easily 
accessible organs, such as the skin or peripheral lymph nodes, transbronchial lung biopsies 
(TBLBs) are recommended.3,4
However, TBLBs are nondiagnostic in approximately a third of patients5,6, and are associated 
with a relatively high morbidity rate (~ 7 %) especially regarding hemoptysis and pneumo-
thorax.7 Additionally, the role of bronchoalveolar lavage (BAL) is debated since it does not 
provide a tissue diagnosis of granulomas and therefore is merely supportive in the diagnosis of 
sarcoidosis.
In recent years, endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) has been 
shown to be a safe and sensitive method (diagnostic yield > 82 %) to detect noncaseating granu-
lomas in cytological smears of patients with a suspicion of sarcoidosis.8-10
However, there is an ongoing discussion regarding needle size and optimal tissue-processing 
method. Recently, in stage I sarcoidosis, Iwashita and colleagues reported a yield of 94 % for the 
assessment of noncaseating granulomas in lymph node aspirates obtained with larger 19-gauge 
needles.11 The optimal yield in the detection of granulomas that includes the use of cell blocks 
obtained from 22-gauge needle aspirates is unknown.
In the present study we investigated the yield in the detection of noncaseating granulomas 
when cell-block processing was added to conventional cytological smear examination of aspi-
rates obtained using 22-gauge needles.
In addition, we assessed the optimal number of needle passes and the difference in yield 
between stage I and II sarcoidosis.
PAtIents And methods
Patients
At our hospital, EUS-FNA is often used as the diagnostic test of choice to confirm noncase-
ating granulomas in patients with suspected sarcoidosis. In the present study, data from all 
consecutive patients who were scheduled, between 2004 and 2009, to undergo EUS-FNA for 
a tissue confirmation of noncaseating granulomas were retrospectively analyzed.
Of these 101 patients (54 % men, 46 % women; mean age 44 years, range 22 – 79) with 
suspected sarcoidosis stage I (54 %) or stage II (46 %), 56 patients (55 %) had previously under-
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gone a nondiagnostic fiberbronchoscopy in which the following interventions were performed: 
TBLB, n = 21; transbronchial needle aspiration (TBNA), n = 18; endobronchial biopsy (EBB), 
n = 13; BAL, n = 29.
eus-fnA
All EUS-FNA procedures were performed on an outpatient basis in the Leiden University 
Medical Center, a tertiary referral center for EUS-FNA, by two experienced pulmonologists 
(K.F.R., J.T.A.).
Investigations were done with patients under conscious sedation with midazolam (1 to 
5 mg intravenously) and were performed using a linear Pentax FG-34UX echo endoscope in 
combination with a Hitachi EUB-6500 ultrasound scanner. A standardized examination of 
all mediastinal nodal regions that can be detected from the esophagus was carried out and 
ultrasound characteristics of the mediastinal lymph nodes were described (Figure 1). The 
presence or absence of multiple, clustered lymph nodes with well-demarcated borders and a 
homogeneous isoechoic echo texture was noted. Aspirates from mediastinal lymph nodes were 
obtained under real-time ultrasound-guided FNA with 22-gauge needles (Hancke/Vilmann, 
GIP/MEDI-Globe, or Cook Medical) either with or without vacuum suction.
figure 1. Endoscopic ultrasound (EUS) image of the subcarinal space, with multiple, isoechogenic, well-demarcated 
lymph nodes (LN) located between the esophagus (ES), pulmonary artery (PA) and the left atrium (LA) (station 7).
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handling of eus aspirates
EUS aspirates were expelled from the needle either by blowing air through a 50-ml syringe 
or by reinsertion of the stylet. Aspirates were smeared on glass slides and a proportion of 
slides were taken for on-site evaluation and colored with Diff-Quick staining (Kit RAL-555; 
Reactifs RAL, Martillac, France) for adequacy assessment by the EUS investigators (J.T.A. or 
K.F.R.) during the EUS procedure. After the procedure, all slides were sent for interpretation 
by an experienced cytopathologist (M.V.C.) and all uncolored slides were stained with May-
Grünwald-Giemsa at the Department of Pathology.
In the absence of identification of granulomas at on-site screening, or if the obtained material 
was abundant or very bloody, the fine-needle aspirates were also processed for cell-block evaluation. 
For this purpose, the aspirate was collected in a formalin-embedded sample tube using the needle 
stylet. In the laboratory, the sediment obtained was processed with a cytoblock kit (Shandon Cell 
Block Preparation System; Thermo Scientific, Pittsburgh, Pennsylvania, USA) and embedded in 
paraffin blocks; thereafter the histological slides were stained with hematoxylin–eosin.
To assess the optimal number of needle passes for an optimal yield, all slides were labeled 
with the number of the needle pass in which the specimen was obtained.
In patients in whom mediastinal tuberculosis was also considered aspirates were sent for 
polymerase chain reaction (PCR) analysis and culture of Mycobacterium tuberculosis.
final diagnosis and data analysis
The final diagnosis of sarcoidosis was based on clinical and radiological suspicion, tissue con-
firmation of noncaseating granulomas, and a follow-up period after which similarly presenting 
diseases such as lung cancer, lymphoma or tuberculosis could be excluded.
Lymph node aspirates obtained by EUS-FNA were considered to be representative if non-
caseating granulomas or nodal lymphoid tissue were found, or if the aspirate contained other 
cellular material that resulted in a specific diagnosis.
The sarcoidosis staging was, by definition, based on a chest X-ray done prior to the inves-
tigation. Stage I is defined as hilar and/or mediastinal lymphadenopathy without pulmonary 
involvement. Stage II is defined as hilar and/or mediastinal lymphadenopathy with the pres-
ence of pulmonary involvement.4
The sensitivity of EUS-FNA for the assessment of noncaseating granulomas was calculated 
as the number of patients in whom EUS demonstrated granulomas as a proportion of the total 
of patients with a final diagnosis of sarcoidosis.
To find the optimal number of needle passes, the cumulative sensitivity for successive needle 
passes was calculated as follows: the number of patients in whom a particular needle pass gave the 
first confirmation of granulomas was added to the total already having an EUS confirmation, and 
this new total was divided by the total number of patients with a final diagnosis of sarcoidosis).






Standardized EUS examination of the mediastinal nodes was feasible in 100 patients (99 %) 
(Figure 2), while introduction of the EUS scope in the esophagus was not possible in a single 
patient because of extreme sensitivity of the pharynx.
Aspirates of mediastinal lymph nodes were obtained in all patients, with an average of 3.9 
needle passes (range 1 – 7) per patient.
Aspirated lymph nodes were located in the paratracheal areas (stations 2R, 4L, 4R) in 21 
patients (21 %), in the aortopulmonary window (station 5) in 5 patients (5 %), the subcarinal 
area (station 7) in 97 patients (97 %) and in the lower paraesophageal region (stations 8L, 8R) 
in 9 patients (9 %).
Cytological smear examinations were done for all 100 patients and cell-block analysis was 
available for 76 (76 %).
Cytological smears showed noncaseating granulomas without necrosis in 72 patients (Figure 
3), noncaseating granulomas with necrosis in 1, reactive lymph node tissue with loose epithe-
lioid cells in 4, reactive nodal tissue with giant cells in 1, non-small-cell lung carcinoma in 2, 
Reed–Sternberg cells in 1, and reactive nodal tissue in 11, and the aspirate from 8 patients 
contained nonrepresentative material.
Patients with suspicion of sarcoidosis, stage I or II
n =101






No noncaseating granulomas:  n = 21
 Non-small-cell lung carcinoma:  n =   2
   Reed–Sternberg cells: n =   1
   Reactive nodal tissue: n = 13
   Nonrepresentative material: n =   5 
Sarcoidosis
n = 91
Other diagnoses:  n = 9
   Non-small-cell lung carcinoma:  n = 3
   Lymphoma:  n = 2
   Atypical mycobacteriae: n = 1
   Extrinsic allergic alveolitis:  n = 1

























Fig. 2 Study flow chart for patients with suspected pulmonary sarcoidosis
(stage I/II), scheduled for endoscopic ultrasound-guided fine-needle as-
piration (EUS-FNA).
figure 2. Study flow chart for pa-
tients with suspected pulmonary 
sarcoidosis (stage I/II), scheduled for 
endoscopic ultrasound-guided fine-
needle aspiration (EUS-FNA).
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Cell blocks of the EUS aspirates demonstrated noncaseating granulomas without necrosis in 
41 patients, reactive nodal tissue with giant cells in 1, non-small-cell lung carcinoma in 1, and 
reactive nodal tissue in 11 and the cell blocks from 22 patients contained nonrepresentative 
material.
Cytology and cell-block investigation together detected noncaseating granulomas in 79 
patients. In 18 patients without noncaseating granulomas in cytological smears, cell-block 
analysis confirmed granulomas in 6 (33 %). Tissue that was representative of mediastinal lymph 
nodes was obtained for 95 patients (95 %).
Culture and PCR analysis for M. tuberculosis were done for 28 patients (28 %) and were 
negative for all.
further diagnoses and follow-up
Among the 21 patients without granulomas at endoscopic ultrasound, EUS-FNA found 
non-small-cell lung carcinoma in two and non-Hodgkin lymphoma (Reed–Sternberg cells) 
in one. In five patients, granulomas were subsequently found, by mediastinoscopy (n = 3), 
bronchoscopy with transbronchial biopsy (n = 1), and by nodal excision in the groin (n = 1). 
One patient was diagnosed by means of bone biopsy with metastasized adenocarcinoma of 
unknown origin, one patient with malignant lymphoma by mediastinoscopy, and in one 
patient PCR analysis was positive for atypical mycobacteriae. The ten remaining patients were 
clinically and radiologically followed.
For the whole cohort, follow-up was available for a median period of 18 months (range 
1 – 53) and follow-up for a period of at least 6 months was available for 90 patients (90 %).
final diagnosis
A final diagnosis of sarcoidosis was made in 91 patients (91 %). The other diagnoses were 
non-small-cell lung carcinoma in three (3 %), malignant lymphoma in two (2 %), atypical my-
figure 3. a Cytological smear with loosely aggregated epithelioid histiocytes (granuloma) without necrosis. b Small tis-
sue fragment from the cell block containing epithelioid granulomas without necrosis, surrounded by lymphoid tissue.
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cobacterial infection in one (1 %), extrinsic alveolitis in one (1 %) and reactive lymphadenitis 
in two (2 %).
Based on cytological smears and cell-block analysis together, EUS-FNA detected noncaseat-
ing granulomas in 79 patients (87 %).
The sensitivity for stage I sarcoidosis was 92 % (n = 52), whereas it was 77 % for stage II 
(n = 39).
The sensitivity of EUS-FNA for the detection of granulomas in patients without a previous 
bronchoscopy (n = 40), a previous bronchoscopy with tissue sampling (TBLB, EBB, TBNA) 
(n = 43) and a previous bronchoscopy with only BAL (n = 8) was 93 %, 84 % and 63 %, respec-
tively.
The cumulative sensitivity of EUS-FNA for the confirmation of noncaseating granulomas 
with one, two, three, and four needle passes was 55 %, 77 %, 80 %, and 86 %, respectively. 
Additional needle passes after the fourth one did not notably increase the diagnostic yield 
(Table 1).
In patients with a final diagnosis of sarcoidosis, EUS features suggestive for sarcoidal involve-
ment (multiple, clustered isoechoic lymph nodes) (Figure 1) were noted in 79 patients (87 %). 
In the other 12 patients, lymph nodes were either small and nonsuspicious (< 10 mm, oval-
shaped, vaguely demarcated borders) (n = 5), consisted of only a solitary, isoechoic enlarged 
lymph node (n = 5), or presented with inhomogeneous echo features (n = 2).
safety
One serious complication (1 %) occurred in a 49-year-old woman with a final diagnosis of 
sarcoidosis who developed fever and retrosternal pain, 2 days after EUS-FNA of subcarinal 
and lower paraesophageal lymph nodes in which noncaseating granulomas were found. She 
reported to the hospital 10 days after developing symptoms, and computed tomography (CT) 
images showed local abscesses in the biopsied mediastinal area. During thoracotomy, necrotic 
lymph node tissue was removed after which the patient recovered completely.
table 1. The cumulative sensitivity of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) for the detec-
tion of non-caseating granulomas for consecutive fine needle passes, in 91 patients with a final diagnosis of sarcoidosis.
Needle passes 
(FNA) 
Patients receiving this 
needle pass, n
Number of patients in whom this needle pass 
demonstrated granulomas for the first time, n
Cumulative sensitivity in 
detecting granulomas
1st 91 50 56 %
2nd 91 20 77 %
3rd 79 3 80 %
4th 54 5 86 %
5th 26 0 86 %
6th 9 0 86 %
7th 4 1 87 %
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Minor adverse effects were recorded in two other patients with a final diagnosis of sarcoidosis 
(2 %). In one patient a small local hematoma was seen on ultrasound images directly after FNA 
of a subcarinal lymph node and another patient complained of painful swallowing following 
EUS.
dIsCussIon
In patients with suspected sarcoidosis, EUS-FNA with 22-gauge needles demonstrated nonca-
seating granulomas in 87 % (n = 79) by aspiration of mediastinal lymph nodes (conventional 
cytology plus cell-block investigation). The addition of cell-block analysis to cytological smear 
examination of EUS fine-needle aspirates reduced the false-negative rate by 33 %. The yield of 
EUS-FNA for the detection of noncaseating granulomas was optimal when four needle passes 
were performed. The diagnostic accuracy for radiological stage I sarcoidosis was 92 %, whereas 
it was 77 % for stage II disease.
The observed high yield in assessing noncaseating granulomas in the present cohort of 
patients with a suspicion of sarcoidosis confirms the findings of other smaller studies.
In our previous published paper, reporting on another 51 patients, we found a diagnostic 
accuracy of 82 % based on cytology without cell-block analysis.8 Other studies have reported 
sensitivities of 86 % – 100 % in patients with sarcoidosis.9-12
In the present study, six potential false-negative EUS-FNA outcomes were prevented because 
cell-block analysis demonstrated granulomas whereas conventional cytological smears did not. 
This additional value of the cell-block investigation may be explained by the way the cell block 
is processed for diagnostic analysis. Noncaseating granulomas are characterized by groups of 
epithelioid cells and the structure of these cells could be disrupted when the aspirates are 
smeared between two glass slides. Material obtained by FNA and subsequently collected in a 
paraffin-embedding container is not liable to this disruption of the anatomical structure.
Regarding granuloma detection, Iwashita et al. demonstrated an added value of histological 
examination (94 %) over cytological smear (78 %) in 41 patients with stage I sarcoidosis, using 
a 19-gauge needle.11 In the present study, a similar sensitivity for stage I sarcoidosis (92 %) was 
obtained in 52 patients with 22-gauge needles when cytological smear and cell-block analysis 
of fine-needle aspirates were combined.
When comparing our study with that of Iwashita et al., some practical differences regarding 
the handling of the material should be noted. In the study of Iwashita et al., “whitish” samples 
were handpicked from the glass slides and subsequently separated from the rest of the fine 
needle aspirate. In the present study, the aspirates for cell-block evaluation were simply sprayed 
into a formalin tube.
Collecting the major part of the aspirates in a tube for cell-block analysis also avoids a large 
number of glasses being sent to the pathologist, since nodal aspirates of patients with sarcoid-
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osis are often bloody, and processing them all on glass slides greatly increases the workload for 
cytopathologists.
In the present study, we demonstrated that with four needle passes, an optimal yield can be 
obtained for the detection of granulomas. Therefore, at least four needle passes are advised in 
the absence of on-site cytology.
Although the complication rate with 19-gauge needles seems to be similar to that with 
22-gauge needles, it has been reported that 19-gauge needles are stiffer and less maneuverable 
compared with 22-gauge needles.13
The diagnostic accuracy of EUS-FNA for noncaseating granulomas was significantly higher 
for stage I (92 %) than for stage II (77 %) sarcoidosis. The cause of the lower yield in stage 
II sarcoidosis is unknown and might be explained by a lower density of granulomas or the 
presence of more fibrotic nodes.
Alternative diagnostic methods for pulmonary sarcoidosis include endobronchial 
ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), TBLB, TBNA, and EBB. 
EBUS-TBNA has been shown to obtain yields similar to those of the present study for the 
confirmation of noncaseating granulomas (range 85 % – 96 %).14-16 To date, no study has been 
done that has compared the value of EUS-FNA versus EBUS-TBNA in patients with suspected 
sarcoidosis.
With TBLB, described by the 1999 WASOG/ERS/ATS consensus statement as the advised 
diagnostic method, approximately one third of patients remain non-diagnostic5,6 and the 
technique is associated with a 7 % risk of pneumothorax or bleeding (> 50 ml).7 The yield of 
transbronchial needle aspiration (TBNA) is also modest, at just over 60 %.17,18 Although it 
has been advocated that a bronchoalveolar lavage (BAL) with an increased CD4/CD8 ratio 
is very specific for the diagnosis of sarcoidosis19, several studies have reported highly variable 
results.20-22
In the present study, one serious complication was observed when a lymphadenitis with 
abscess formation developed after EUS-FNA. Whether treatment with antibiotics, directly 
after the onset of symptoms would have altered the course of infection is unknown. In the 
study of Iwashita et al., one patient also developed a mediastinitis after EUS-FNA.11
Several limitations apply to this study. First of all, only patients with stage I and II sarcoidosis 
were included in this analysis and therefore the data only apply to these stages. Secondly, the 
prevalence of tuberculosis in our geographical area is low and other granulomatous diseases 
such as histoplasmosis or berylliosis are also rarely seen. Therefore, in terms of external validity, 
this study is only applicable to regions where these diseases are similarly prevalent. Also, PCR 
analysis and culture for M. tuberculosis was not performed for every patient.
Furthermore, the study setting is a tertiary referral centre and patients with suspected sar-
coidosis are mostly referred for a tissue confirmation of sarcoidosis because they present with 
active symptoms, which might represent a patient group in which there is a high chance of 
finding noncaseating granulomas.
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Finally, material for cell-block evaluation was not obtained in every patient. Cell-block 
analysis was performed in the absence of granulomas in the first smear during on-site evalua-
tion, or when the acquired material was abundant or very bloody. The latter may explain why 
no representative material was found in one third of the cell blocks.
In conclusion, EUS-FNA with 22-gauge needles is a feasible, safe, and highly diagnostic 
technique for the tissue confirmation of noncaseating granulomas in patients with suspected 
sarcoidosis.
Regarding granuloma detection, cell-block analysis added to conventional cytological smears 
reduces the false-negative rate considerably, and should therefore be used routinely in all pa-
tients who undergo EUS-FNA for the diagnosis of sarcoidosis. EUS has a substantially higher 
yield for stage I compared with stage II sarcoidosis. For an optimal yield in the detection of 
granulomas, a minimum of four needle passes are advised in the absence of on-site cytological 
evaluation.
A randomized, prospective study between ultrasound-guided fine-needle aspiration of 
mediastinal or hilar lymph nodes (by either EUS-FNA or EBUS-TBNA) and transbronchial 
biopsies for the assessment of noncaseating granulomas is indicated, to investigate the optimal 
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Tissue verification of noncaseating granulomas is recommended for the diagnosis of sarcoidosis. 
Bronchoscopy with transbronchial lung biopsies, the current diagnostic standard, has moder-
ate sensitivity in assessing granulomas. Endosonography with intrathoracic nodal aspiration 
appears to be a promising diagnostic technique.
Objective 
To evaluate the diagnostic yield of bronchoscopy vs endosonography in the diagnosis of stage 
I/II sarcoidosis.
Design, Setting, and Patients 
Randomized clinical multicenter trial (14 centers in 6 countries) between March 2009 and 
November 2011 of 304 consecutive patients with suspected pulmonary sarcoidosis (stage I/II) 
in whom tissue confirmation of noncaseating granulomas was indicated.
Interventions 
Either bronchoscopy with transbronchial and endobronchial lung biopsies or endosonography 
(esophageal or endobronchial ultrasonography) with aspiration of intrathoracic lymph nodes. 
All patients also underwent bronchoalveolar lavage.
Main Outcomes and Measures 
The primary outcome was the diagnostic yield for detecting noncaseating granulomas in pa-
tients with a final diagnosis of sarcoidosis. The diagnosis was based on final clinical judgment 
by the treating physician, according to all available information (including findings from initial 
bronchoscopy or endosonography). Secondary outcomes were the complication rate in both 
groups and sensitivity and specificity of bronchoalveolar lavage in the diagnosis of sarcoidosis.
Results
A total of 149 patients were randomized to bronchoscopy and 155 to endosonography. Signifi-
cantly more granulomas were detected at endosonography vs bronchoscopy (114 vs 72 patients; 
74% vs 48%; P < .001). Diagnostic yield to detect granulomas for endosonography was 80% 
(95% CI, 73%-86%); for bronchoscopy, 53% (95% CI, 45%-61%) (P < .001). Two serious 
adverse events occurred in the bronchoscopy group and 1 in the endosonography group; all 
patients recovered completely. Sensitivity of the bronchoalveolar lavage for sarcoidosis based 
on CD4/CD8 ratio was 54% (95% CI, 46%-62%) for flow cytometry and 24% (95% CI, 
16%-34%) for cytospin analysis.
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Conclusion and Relevance
Among patients with suspected stage I/II pulmonary sarcoidosis undergoing tissue confir-
mation, the use of endosonographic nodal aspiration compared with bronchoscopic biopsy 
resulted in greater diagnostic yield.




Sarcoidosis is a multisystem granulomatous disease of unclear etiology, with an estimated life-
time risk of 1% to 2%.1 The incidence of sarcoidosis in the United States is high, with up to 40 
cases per 100 000, and sarcoidosis-related mortality is increasing.2,3 The disease is characterized 
by tissue accumulation of noncaseating granulomas and affects the lungs and intrathoracic 
lymph nodes in almost all patients.4
A diagnosis of sarcoidosis is based on clinical and radiologic suspicion, tissue confirmation 
of noncaseating granulomas, and exclusion of similar presenting diseases such as tuberculosis, 
lymphoma, and lung cancer.5,6 In the absence of easily accessible biopsy sites (skin or superficial 
lymph nodes), flexible bronchoscopy with transbronchial lung biopsies (TBLBs) is recom-
mended.5 TBLB, however, has moderate sensitivity (60%) to detect granulomas even when 
combined with endobronchial biopsies.7- 9 Additionally, TBLB is associated with hemorrhage 
and pneumothorax in up to 6% of patients.10
Tissue confirmation of noncaseating granulomas can alternatively be obtained by sampling 
intrathoracic lymph nodes under ultrasonographic guidance from the airways (endobronchial 
ultrasonography[EBUS]-guided transbronchial needle aspiration [TBNA]) or the esophagus 
(transesophageal ultrasonography[EUS]-guided fine-needle aspiration). The detection rate of 
noncaseating granulomas for endosonography is approximately 80%.11- 14
We performed a randomized controlled trial comparing conventional bronchoscopy (in-
cluding transbronchial and endobronchial mucosal biopsies) with endosonography (EUS or 
endobronchial ultrasonography–guided nodal aspiration) for the detection of noncaseating 
granulomas in patients with suspected pulmonary sarcoidosis. Additionally, we performed 
bronchoalveolar lavage (BAL) in all patients to assess its utility in diagnosing sarcoidosis.
methods
Patients
Patients older than 18 years, with a clinical and radiologic suspicion of sarcoidosis stage I 
(mediastinal or hilar lymphadenopathy) or II (lymphadenopathy and intraparenchymal ab-
normalities), and with an indication for tissue verification of noncaseating granulomas were 
eligible for inclusion. The decision to obtain tissue for diagnostic purposes vs a clinical and 
radiologic follow-up was made in dialogue between the treating physician and the patient. 
Previous diagnostic evaluation consisted of a conventional evaluation (medical history, physical 
examination, and laboratory tests) with radiograph and computed tomography of the chest. 
Exclusion criteria were obvious organ involvement of sarcoidosis with the possibility to con-
firm granulomas with a minimally invasive diagnostic procedure (eg, biopsy of skin lesions or 
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superficial lymph nodes), Lofgren syndrome, inability to undergo endoscopy, pregnancy, or 
inability to consent.
Candidates for study participation were identified in 14 university and regional hospitals 
in the Netherlands, Belgium, Germany, Denmark, Poland, and the United Kingdom between 
March 2009 and November 2011 (Leiden University Medical Center; Radboud University 
Hospital Nijmegen; Medical Center Haaglanden; Catharina Hospital Eindhoven; St. Fran-
ciscus Hospital Rotterdam; Rijnstate Hospital Arnhem; Erasmus University Medical Center 
Rotterdam; Thoraxclinic Heidelberg; Hospital Grosshansdorf; John Paul II Hospital Krakow; 
Pulmonary Hospital Zakopane; Gentofte Hospital Copenhagen; Royal Brompton Hospital 
London; Gent University Hospital). This investigator-initiated trial, registered under the acro-
nym GRANULOMA, was approved by the human research ethics committee at each center, 
and written informed consent was obtained from every participant before randomization.
study design
This was an investigator-initiated, unblinded, randomized trial. Block randomization was 
performed, stratified by center, with variable block sizes (randomly chosen between 4 and 8 
blocks). Randomization software determined the random allocation (drawn from a uniform dis-
tribution). For all patients, the random-sequence allocation remained concealed until consent. 
Patients were assigned 1:1 to either conventional bronchoscopy with TBLB and endobronchial 
mucosal biopsy (bronchoscopy group) or to endosonography (esophageal or endobronchial) 
ultrasonography-guided mediastinal or hilar lymph node aspiration (endosonography group). 
For all patients, bronchoscopy with BAL was performed. Patients were enrolled at each site by 
the local study coordinator.
Nodal aspirates and histologic lung and mucosal biopsies were sent to the local pathologist 
for pathologic assessment. In addition, tissue samples were routinely sent in for Auramine/
Ziehl-Neelsen staining, as well as culture and polymerase chain reaction (where available) for 
mycobacterium tuberculosis testing.
For patients without a conclusive diagnosis after endoscopy (ie, biopsies/aspirates without 
granulomas or an alternative diagnosis), it was optional to perform additional tissue sampling 
techniques to obtain a classifying diagnosis (for instance, to perform TBLB after a nondiag-
nostic endosonography result). The diagnosis of sarcoidosis was made by the treating physician 
according to all available information (including the findings from initial bronchoscopy or 
endosonography), using the European Respiratory Society/American Thoracic Society/World 
Association of Sarcoidosis and Other Granulomatous Disorders consensus statement (clini-
cal and radiologic compatibility, presence of noncaseating granulomas, and the exclusion of 
similar presenting diseases).5 Clinical and radiologic follow-up was performed 6 months after 




After completion of the study, all bronchoscopy-obtained biopsies and endosonography-
obtained fine-needle aspirates were blindly reevaluated by a reference pathologist (T.M.) and 
cytologist (F.D.B.), respectively.
definition of end Points
The primary end point was the detection of granulomas or clusters of epithelioid cells concor-
dant with a granulomatous inflammation. False-positive cases were defined as patients receiv-
ing a diagnosis of sarcoidosis after bronchoscopy or endosonography but for whom during 
follow-up another diagnosis was made. Diagnostic yield of granuloma detection was defined 
as the number of patients with detected granulomas or clusters of epithelioid cells obtained 
by the initial diagnostic procedure divided by the number of patients with a final diagnosis of 
sarcoidosis.
The rate of (serious) adverse events related to the diagnostic procedures was a secondary end 
point. Sensitivity and specificity of the BAL were also secondary end points. The sensitivity of 
the BAL (for flow cytometry or cytospin analysis) was calculated as the proportion of patients 
with CD4/CD8 ratio ≥3.5 among patients receiving a diagnosis of sarcoidosis. The specificity 
was calculated as the proportion of patients with CD4/CD8 ratio <3.5 among patients with a 
diagnosis other than sarcoidosis.
diagnostic Procedures
In the bronchoscopy group, conventional bronchoscopy was performed, including a complete 
endobronchial inspection followed by BAL. Bronchoalveolar lavage was performed preferably 
in the middle lobe or lingula with 150 to 200 mL of saline, according to the guidelines of the 
European Respiratory Society.15 Lymphocyte percentage within inflammatory cells counted 
and CD4/CD8 ratio were assessed with either cytospin or flow cytometry analysis. Subse-
quently, at least 4 TBLB and 4 endobronchial mucosal biopsy samples were obtained.
In the endosonography group, EUS or endobronchial ultrasonography-guided TBNA was 
performed with linear echo-endoscopes, using 22-gauge needles, as previously described.16,17 
The decision to perform an esophageal or endobronchial procedure was left to the local in-
vestigator and could depend on equipment availability, computed tomography findings, or 
preference of either physician or patient. During endosonography, a systematic evaluation of 
the intrathoracic nodes was made and samples were to be taken from easily accessible nodes, 
often the subcarinal area. On-site cytologic evaluation was optional. In absence of on-site 
evaluation, a minimum of 4 nodal aspirates were to be obtained and processed for cytologic 
smearing and preferably cell block analysis. Flexible bronchoscopy with BAL, as described 
above, was performed immediately after EUS fine-needle aspiration or before endobronchial 
ultrasonography-guided TBNA.
Sedation was performed according to institutional practice. Vital signs were monitored 
and the duration of the procedure was recorded. Immediate procedure-related adverse events 
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were documented and generally patients were observed for at least 1.5 hours after endoscopy. 
Patients were instructed to report symptoms (eg, persistent cough, fever, chest pains) occurring 
in the days and weeks after the procedure. Adverse events occurring immediately up to 1 week 
after the study procedure were assessed routinely. Later complications were evaluated in the 
event patients reported symptoms. Data were entered with web-based case report forms at 
randomization, 2 weeks after the endoscopy, and after 6-month follow-up.
statistical Analysis
We hypothesized that the diagnostic yield for granuloma detection would be 70% for bron-
choscopy7- 9 and 85% for endosonography.11- 14 With this assumption, we estimated that 300 
patients would provide a power of 80% with a 2-sided α level of .05, assuming an 80% esti-
mated prevalence of sarcoidosis and compensating for a 5% dropout rate. The primary analysis 
was intention to treat based on randomization. A single patient who was lost to follow-up after 
randomization but before scheduled endoscopy was excluded from analysis. The interobserver 
agreement between the initial pathology assessment and the reference pathology outcome was 
determined by κ measurement of interobserver agreement. χ2 and Fisher exact tests were used 
for the analysis of categorical data and to compare the sensitivity of both endosonography 
and bronchoscopy. Independent t tests were used to compare groups of continuous, normally 
distributed variables. CIs of binominal distributions were calculated with the Clopper-Pearson 
method.
Analyses were performed with SPSS version 20.0. P < .05 was considered statistically sig-
nificant.
results
Between March 2009 and November 2011, 366 consecutive patients with suspected sarcoidosis 
were assessed for study eligibility. A total of 62 patients were excluded and 304 were random-
ized: 149 to conventional bronchoscopy and 155 to endosonography (Figure 1). One patient 
randomized to the endosonography group did not attend any procedure or follow-up and was 
excluded from analysis. One patient randomized to bronchoscopy insisted later on undergoing 
endosonography and another patient randomized to endosonography inadvertently underwent 
bronchoscopy. These 2 patients were analyzed in accordance with the groups to which they 
were randomized (ie, with the intention to diagnose). Thus, 301 patients underwent endoscopy 
according to the protocol.
At baseline, patients in both groups were well balanced for major characteristics (Table 
1). Patients were predominantly men (62% [bronchoscopy group] vs 58% [endosonography 
group]), with a mean age of 41 vs 45 years. Fatigue (63%; 95% CI, 58%-96%) and cough 
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CI, 26%-37%) reported nocturnal sweating (20%; 95% CI, 16%-25%), weight loss (22%; 
95% CI, 17%-27%), or both (9%; 95% CI, 6%-12%). The onset of symptoms before ran-
domization was 4 months in both groups. Fifty-three percent of bronchoscopy patients (95% 
CI, 44%-61%) and 44% of endosonography patients (95% CI, 36%-52%) had pulmonary 
opacities on chest radiography.







Age, mean (SD), y 41.2 (11.6) 44.7 (12.3)
Male sex 92 (62) 90 (58)
Symptoms
Fatigue   99 (66) 94 (61) 
Cough  79 (53) 90 (58) 
Dyspnea  83 (56) 72 (47) 
Arthralgia  61 (41) 58 (38) 
Weight loss  32 (21) 34 (22) 
Fever  19 (13) 26 (17) 
Night sweats  36 (24) 25 (16) 
Skin lesions  28 (19) 25 (16) 
Eye lesions  22 (15) 22 (14) 
Onset of symptoms, median (25th-75th percentile), mo 4.0 (2-7) 4.0 (2-6)
Smoking history
Never 92 (62) 94 (61) 
Former 39 (26) 36 (23) 
Quit 18 (12) 24 (15) 
Chest radiograph
Lymphadenopathy 130 (87) 140 (91) 
Pulmonary opacities  78 (52) 67 (44) 
CT scan of the thorax
Lymphadenopathy a 147 (99) 153 (99) 
Maximal nodal short-axis – mean (SD), mmb 18.8 (6.9) 19.4 (7.0) 
Pulmonary opacities  106 (71) 92 (60) 
Sarcoidosis stage, based on chest radiograph
I 69 (46) 85 (55) 
II 79 (53) 68 (44) 
III  1 (1) 1 (1) 
Abbreviations: CT, computed tomography; EBB, endobronchial biopsy; EBUS, endobronchial ultrasound; EUS, 
esophageal ultrasound; TBLB, transbronchial lung biopsy.
Percentages may not sum to 100% because of rounding. Results on 1 patient are missing (see Figure 1)
aLymphadenopathy was defined as a minimal short axis > 10 mm.
bMean short-axis for EUS patients was 19.0 mm(SD, 7.0); for EBUS, 20.6 mm (SD, 7.1)
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Mean duration of the procedure was 20 minutes for bronchoscopy (range, 7-37) vs 29 
minutes for endosonography (range, 7-60). The majority of procedures were performed under 
conscious sedation, usually with midazolam (bronchoscopy, 66%; endosonography, 79%), and 
general anesthesia was used in 14% of the bronchoscopy group and 15% of the endosonog-
raphy group. Transbronchial lung biopsies were performed under fluoroscopic guidance in 55 
of 142 patients (39%). Bronchoalveolar lavage was performed in all patients and processed for 
analysis in 285 of 303 patients (94%) by flow cytometry (175/285 patients; 61%) and cytospin 
(110/285 patients; 39%). Further procedural endoscopy details are provided in Table 2.
final diagnoses
The final diagnosis determined at 6 months after randomization was sarcoidosis in 278 of 303 
patients (92%; 95% CI, 88%-95%) (bronchoscopy, 91%, 95% CI, 86%-95%; endosonogra-
phy, 92%, 95% CI, 87%-96%), which was based on tissue-proven granulomas in 250 of 278 
patients (90%; 95% CI, 86%-93%) and in 28 of 278 patients (10%; 95% CI, 7%-14%) on 
clinical and radiologic follow-up (Table 3). Of the 75 patients in the bronchoscopy group for 
whom no diagnosis was available after bronchoscopy, 64 of 75 (85%; 95% CI, 75%-92%) 
underwent additional (endoscopy) procedures, resulting in a disease-classifying tissue diagno-
sis in 47 of 64 (73%; 95% CI, 61%-84%). Of the 36 patients undergoing endosonography 
without a diagnosis after endosonography, 25 underwent additional investigations, in which 
granulomas were found in 16 of 25 (64%; 95% CI, 43%-82%). Auramine/Ziehl-Neelsen 
staining, culture, and polymerase chain reaction for Mycobacterium tuberculosis were performed 
in 295 of 303 patients (97%), 297 of 303 patients (98%), and 200 of 303 patients (66%), 
respectively. Six-month follow-up was completed for 302 of 303 patients (99%); 1 patient did 
not attend follow-up visits. There were no false-positive diagnoses of sarcoidosis.
table 2. Characteristics of endoscopy
Bronchoscopy (n = 149)
No. (%)
Endosonography (n = 154)
No. (%)
tBlB eBB eus-fnA eBus-tBnA
Procedure performed 143/149 (96)a,b 138/149 (93)a 102/154 (66)c 56/154 (36)c
No. of biopsies, mean (SD) 5.24 (1.53) 4.10 (1.03) 5.21 (1.40) 5.75 (2.01)
Patients with ≥4 biopsy specimens collected 139/149 (93) 121/149 (81) 64/68 (94)d 42/43 (98)d
Representative materiale 138/149 (93) 132/149 (89) 97/103 (94) 51/56 (91)
Abbreviations: EBB, endobronchial biopsy; EBUS, endobronchial ultrasonography; EUS, esophageal ultrasonog-
raphy; FNA, fine-needle aspiration; TBLB, transbronchial lung biopsy; TBNA, transbronchial needle aspiration.
aBoth TBLB and EBB were omitted in 2 patients because of restlessness.
bFluoroscopy was used in 39% of patients.
cIn 5 patients, both an EUS and an EBUS were performed.
dIn patients without on-site cytology available (EUS: 68/103, 66% [95% CI, 56%-75%]; EBUS: 43/56, 77% 
[95% CI,64%-87%]).
eThe definition of representative material included a classifying diagnosis or nodal tissue (in case of EUS/EBUS) or 
respiratory epithelium (in case of TBLB/EBB).
Endosonography vs Conventional Bronchoscopy for the Diagnosis of sarcoidosis The GRANULOMA Randomized Clinical Trial 
45
detection of granulomas
Granulomas or epithelioid clusters compatible with a sarcoidlike granulomatous inflammation 
were found significantly more often at endosonography than bronchoscopy (114/154 [74%; 
95% CI, 66%-81%] vs 72/149 [48%; 95% CI, 40%-59%], P < .001) (Table 3).
The diagnostic yield to detect granulomas for endosonography vs bronchoscopy was 80% 
(95% CI, 73%-86%) vs 53% (95% CI, 45%-61%) (P < .001) (Figure 2).
For stage I sarcoidosis, the diagnostic yield of bronchoscopy was 38% (95% CI, 26%-51%) 
compared with 66% (95% CI, 54%-77%) for stage II (P < .001). For endosonography, 
diagnostic yield for stage I was 84% (95% CI, 74%-92%) compared with 77% (95% CI, 
64%-86%) for stage II (P = .24). Endosonography had a significantly higher diagnostic yield 
for stage I sarcoidosis than bronchoscopy (P < .001); for stage II sarcoidosis, the difference was 
not statistically significant (P = .18). Transesophageal ultrasonography-guided fine-needle as-
piration performed better in comparison with endobronchial ultrasonography-guided TBNA, 
with a diagnostic yield of 88% (95% CI, 80%-93%) vs 66% (95% CI, 53%-77%) (P < .01).
In the bronchoscopy group, biopsies demonstrated eosinophilic and granulomatous vascu-
litis in one patient and metastasized thyroid cancer in another. In the endosonography group, 
noncaseating granulomas without necrosis were found in 2 patients, of whom one received a 
diagnosis of tuberculosis; the other, of metastasized non–small cell lung carcinoma. In 2 more 
patients, a non–small cell lung carcinoma and colon carcinoma nodal metastasis were found.







Detection of granulomas, consistent with the diagnosis sarcoidosis 72 (48) 114 (74)
Diagnostic yield of granuloma detection in patients with sarcoidosis 72/136 (53) 114/142 (80)
Final diagnosis
Sarcoidosis 136 (91) 142 (92) 
Other diagnoses 13 (9) 12 (8) 
Post inflammation / reactive mediastinal nodal disease 5 7 
Non-specific interstitial pulmonary fibrosis 3 0 
Tuberculosis 1 1 
Lymph node metastasis of non-  small cell lung cancer 0 2 
Metastatic thyroid cancer  1 0 
Metastatic colon cancer 0 1 
Wegener’s disease 1 0 
Pneumoconiosis 0 1 
Atypical pneumonia 1 0 
Atypical interstitial nodules e.c.i. 1 0 
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Reference pathology was obtained for 95% of patients (288/303). The interobserver agree-
ment for granuloma detection of the TBLB/endobronchial biopsy and the endosonography-
obtained aspirates between the initial pathologist in each hospital and the reference pathologist 
was κ = 0.86 and κ = 0.83, respectively.





Serious adverse events n=2 n= 1
Mediastinal abscess requiring thoracotomy 0 1 
Pneumothorax, drain necessary   1 0 
Ventilatory insufficiency requiring noninvasive ventilation 1 0 
Adverse events 52 30
Ulcus midesophageal 0 1 
Pneumothorax, no drain necessary 6 0 
Major agitation prohibiting adequate protocol sampling 3 0 
Hemorrhage, mL   
>75  1 0 
26-75  1 0 
5-25  4 0 
<5  6 0 
Small mediastinal hematoma 0 1 
Saturation decrease, %   
<60 0 1 
<80 2 0 
80 - 90 6 2 
Loose tooth after endoscopy 0 1 
Introduction EUS scope in trachea 0 1 
Intolerable cough 7 6 
Sore throat 6 11 
Dysphagia 0 2 
Minor aspecific thoracic pain 3 0 
Temperature < 39⁰C 6 2 
Tachycardia 1 0 
Technical issues   
Early removal of  scope because of technical problem 0 1 
Endoscope damage 0 1 
Abbreviations: EBB, endobronchial biopsy; EBUS, endobronchial ultrasonography; EUS, esophageal ultrasonog-
raphy; TBLB, transbronchial lung biopsy.
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Adverse events
In 303 patients, 3 serious adverse events occurred (bronchoscopy, 2/149; endosonography, 
1/154) (Table 4). One patient developed a pneumothorax after TBLB, requiring chest tube 
drainage. Another patient required noninvasive ventilation (<12 hours) because of respiratory 
insufficiency after bronchoscopy under general anesthesia. One patient developed a mediasti-
nal abscess after EUS fine-needle aspiration, requiring thoracotomy and prolonged antibiotic 
treatment.
In total, 82 adverse events occurred: 52 in 44 of 149 patients in the bronchoscopy group 
(30%; 95% CI, 22%-38%) and 30 in 29 of 154 patients undergoing endosonography (19%; 
95% CI, 13%-26%) (P = .03).
The most prevalent adverse event for bronchoscopy was intolerable cough (7/149; 5%; 95% 
CI, 2%-9%), and for endosonography, a sore throat (11/154; 7%; 95% CI, 4%-12%). All 
patients recovered completely.
figure 2. Diagnostic Outcome of Study Procedures Based on Bronchoalveolar Lavage
A receiver operating characteristic (ROC) for the test performance of bronchoalveolar lavage (BAL). Such an ROC 
curve is a graphic plot that illustrates the performance of a binary classifier system as its discrimination threshold is 
varied. It is created by plotting the fraction of true-positives out of the positives (TPR=truepositive rate, sensitivity) 
vs the fraction of false-positives out of the negatives (FPR=false-positive rate, 1_specificity), at various threshold 
settings. The curves for BAL (cytospin and flow cytometry analysis) show all FPR and TPR combinations that can 
be obtained by choosing different cutoff values for the CD4/CD8 ratios. The circles in the BAL curves represent the 
FPR and TPR combinations associated with a cutoff of 3.5, a diagnostic threshold often used in clinical practice. 
The blue circles indicate sensitivity (95% CI) of bronchoscopy and endosonography. EUS indicates transesophageal 





With a CD4/CD8 ratio cutoff value of 3.5, the sensitivity of the BAL for a final diagnosis 
of sarcoidosis was 54% (95% CI, 46%-62%) for flow cytometry and 24% (95% CI, 16%-
34%) for cytospin analysis. The corresponding specificities were 89% (95% CI, 52%-100%) 
and 90% (95% CI, 56%-100%), respectively. The mean percentage of lymphocytes within 
inflammatory cells counted was 29.7% for flow cytometry vs 24.6% for cytospin analysis. The 
receiver operating characteristic curves for the sensitivity and specificity for different CD4/
CD8 ratio cutoff values for flow cytometry and cytospin analysis are depicted in Figure 2.
dIsCussIon
Endosonography with sampling of intrathoracic nodes had higher diagnostic yield in com-
parison with bronchoscopy with TBLB and endobronchial mucosal biopsy in demonstrating 
granulomas in patients with presumed sarcoidosis stage I and II. Serious adverse events related 
to endoscopy were uncommon.
Transbronchial lung biopsies obtained during conventional bronchoscopy are regarded 
as the current standard to demonstrate noncaseating granulomas in patients with suspected 
sarcoidosis in case a tissue diagnosis is indicated.5 The diagnostic yield of TBLB and endo-
bronchial biopsy found in the present study (53%) is within the lower range as reported in 
the literature: 60% (range, 40%-90%).7- 9 In 93% of patients, at least 4 TBLB samples were 
obtained, showing representative alveolar tissue in 93% of cases.
TBLB can be combined with additional diagnostic modalities such as endobronchial biopsy, 
“blind” TBNA of mediastinal lymph nodes, or BAL. In clinical practice, TBLB is often not 
performed because of concern about hemoptysis (up to 4%) or pneumothoraces (up to 2%).10
Endosonography in the present study had a diagnostic yield of 80% to detect noncase-
ating granuloma in patients with suspected sarcoidosis; this is similar to previous findings 
reporting a sensitivity of approximately 80% (range, 54%-100%).11- 14 A recent prospective 
cohort study showed that endosonography had a sensitivity of 71% in diagnosing sarcoidosis 
after a previous nondiagnostic bronchoscopy result.8 Additionally, 2 small prospective studies 
evaluating bronchoscopy and endosonography reported a significantly higher yield for endo-
bronchial ultrasonography-guided TBNA (85%-94%) compared with TBLB (31%-37%) to 
detect granulomas.18,19
An exploratory analysis was performed to compare endosonography and bronchoscopy 
stratified by stage. For stage I sarcoidosis, this study showed higher diagnostic yield of endo-
sonography compared with bronchoscopy in granuloma detection. For stage II sarcoidosis, 
there was still a numeric difference but this was not statistically significant. However, our 
study was not formally powered for subgroup analyses, meaning that these results should be 
interpreted with caution.
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Strengths of the present study are a high percentage of adequately performed endoscopy 
procedures and the international setting across 6 countries in both general and academic 
hospital settings, contributing to the external validity of the results. The high concordance of 
the reference pathologist with the initial assessment for both fine-needle nodal aspirates and 
histology of TBLB and endobronchial biopsy samples is an important finding, as previously 
observed in a small study.20 Additionally, the availability of BAL data in addition to the granu-
loma detection techniques sheds light on how these different diagnostic techniques compare.
Several limitations also apply to the present study. First, granulomatous inflammation was 
not confirmed in all patients with the final diagnosis of sarcoidosis. However, careful 6-month 
follow-up limits the chance of any missed alternative diagnoses. Second, although the study 
was performed across Europe, it remains unknown what the outcomes are in regions with, 
for instance, a high prevalence of tuberculosis or histoplasmosis. Third, conventional blind 
TBNA was not included in the protocol. However, this technique is not widely practiced11 and 
is operator dependent, and its diagnostic yield is inferior to that of endosonography-guided 
TBNA.21 Fourth, because the diagnostic tests that were evaluated (TBLB, endobronchial 
biopsy, and endosonography) could have directly influenced the main outcome (final diagnosis 
of sarcoidosis at 6 months), incorporation bias is present in this study and may artifactually 
increase the apparent test performance characteristics of the diagnostic procedures evaluated.
Serious adverse events were uncommon and all patients recovered. One patient developed a 
mediastinal abscess after EUS fine-needle aspiration of a mediastinal node. Abscess formation 
has been reported in more cases after an esophageal22 but never an endobronchial approach. 
The rate of minor adverse events was higher for bronchoscopy in comparison with endosonog-
raphy, including pulmonary hemorrhage (8.1%) and pneumothoraces (4%) observed at rates 
similar to those reported in the literature.10
The value of a BAL in diagnosing sarcoidosis, as measured by CD4/CD8 ratio analysis with 
a cutoff value of 3.5, was limited, with a diagnostic accuracy in concordance with that in the 
literature.23,24 As expected, flow cytometry provided a higher sensitivity (54%) than cytospin 
analysis (24%). Bronchoalveolar lavage flow cytometry outcomes showed sensitivity similar to 
that of the combination of TBLB and endobronchial biopsy but had a false-positive rate of 
10%.
How will the outcomes of this study affect future diagnostic strategies for patients with 
suspected sarcoidosis? Whether tissue confirmation of granulomas is indicated should be 
critically assessed in light of recent improvements in computed tomography–thorax imaging. 
For patients who require tissue sampling either to confirm sarcoidosis before treatment or to 
exclude similar presenting diseases such as tuberculosis and lymphoma, the outcomes of this 
study indicate that endosonographic evaluation is likely to have the highest diagnostic yield.
In conclusion, among patients with suspected stage I/II pulmonary sarcoidosis undergoing 
tissue confirmation, the use of endosonographic nodal aspiration compared with broncho-
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Sarcoidosis is a disease of unknown etiology mostly affecting young adults and presenting 
with mediastinal or hilar lymphadenopathy in 85% of patients. Endoscopic US-guided FNA 
(EUS-FNA) and endobronchial US-guided transbronchial needle aspiration (EBUS-TBNA) of 
intrathoracic lymph nodes is increasingly used for the diagnosis of pulmonary sarcoidosis. Com-
plications are rare; severe procedure-related infections have been reported in only 2 patients. 
One patient developed mediastinitis and another a mediastinal abscess after EUS-FNA.1,2 This 
case series describes 5 patients with suspected sarcoidosis who developed mediastinal abscesses 
after EUS-FNA, necessitating surgical treatment in 4 patients.
mAterIAls And methods
We retrospectively reviewed records of all patients with a final diagnosis of sarcoidosis who 
had undergone EUS or EBUS of mediastinal/hilar lymph nodes in two university hospitals. 
Between 1999 and 2011, Leiden University Medical Center (LUMC) (n=184) and Radboud 
University Medical Center (n=68) investigated 252 patients. Five patients (LUMC [n=3], 
Radboud [n=2]) developed mediastinal abscesses after EUS-FNA. One case has been reported 
previously.2
The LUMC and Radboud UMC are both tertiary-care hospitals, and the pulmonary depart-
ments are referral centers for mediastinal analysis with endosonography. EUS-FNA has been 
used as a routine test in daily clinical practice for the assessment of granulomas in patients 
suspected of sarcoidosis. Informed consent was obtained in all patients. Investigations were 
performed with the patients under conscious sedation, with 22-gauge needles, and mostly with 
on-site cytology, as previously described.2 Immediate complications were assessed routinely; 
later complications were recorded after patients’ complaints.
results
Case description
A 30-year-old man without comorbidities was referred for fatigue and arthralgia with bilateral 
hilar and mediastinal lymphadenopathy. On the suspicion of sarcoidosis, EUS-FNA was per-
formed, showing coalescing, iso-echogenic, subcarinal lymph nodes (short axis 25 mm). No 
complications were observed during the 8 nodal aspirations showing noncaseating granulomas. 
Fifteen days after EUS, the patient felt retrosternal pain—increasing with breathing/swallow-
ing—and had cough and fever. Inflammatory test parameter results were elevated, and a CT 
scan of the chest revealed a subcarinal mass (4.3 x 4.1 x 3.8 cm—evidently increased compared 
to the before-EUS CT) with thick walls and a hypodense center, consistent with a mediastinal 
abscess (Fig. 1). Culture of the aspirate was positive for Streptococcus salivarius and Staphylococ-
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figure 1. Chest CT images of the 
subcarinal area (lymph node station 
7) before EUS-guided FNA. 1, 15 
days after procedure. 2, 2 days later 
when symptoms of dysphagia exist-
ed. 3, Hypodense centers were seen 
centrally in the subcarinal lymph 
nodes, compatible with abscess for-
mation. The small arrows indicate 
the border of the enlarged subcarinal 
lymph nodes (2 and 3). The position 
of the esophagus is indicated by OE. 
RMB, right main bronchus; LMB, 
left main bronchus; LN7, lymph 
node station 7; OE, esophagus; 
HDS, hypodense centers.
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cus aureus but negative for Mycobacterium tuberculosis. The patient was admitted to the hospital 
and treated with intravenous antibiotics (amoxicillin / clavulanic acid, metronidazole followed 
by penicillin / metronidazole / flucloxacillin). Despite this regimen, the patient developed pro-
gressive dysphagia and maintained intermittent periods of fever during the following 2 days. 
Repeat CT showed progression of the subcarinal mass to 5.8 x 5.0 x 3.6 cm. Subsequently, 
a thoracotomy was performed, with drainage of the abscess. With chest tube drainage and 
antibiotics, clinical conditions improved in 1 week, and the patient was discharged 1 week 
later. Pus culture of the abscess showed Actinomyces, for which clindamycin treatment was 
administered for 4 weeks. At 2 months of follow-up, the patient had fully recovered.
Case description
A 49-year-old woman with a history of salpingitis and iodine-treated goiter was referred for 
dyspnea on exertion and arthralgia. A CT scan showing mediastinal and bilateral hilar lymph-
adenopathy was compatible with stage I sarcoidosis. At EUS, multiple, conflating, isoechoic, 
subcarinal, and lower paraesophageal lymph nodes (15 mm) were sampled 4 times. Aspirates 
showed granulomas without necrosis. Two days after the uneventful procedure, the patient 
developed fever and retrosternal pain, only to report these symptoms 10 days later. By then, 
inflammatory test parameter results were elevated, and a CT scan showed a large, inhomoge-
neous, subcarinal mass (7 x 7 cm) with septa, consistent with abscess formation. Intravenous 
gentamicin / metronidazole / floxacillin was started because her clinical condition failed to 
improve. Subsequently, a posterolateral thoracotomy was performed 5 days later during which 
necrotic nodes in the subcarinal space (10 x 6 x 4 cm) were removed, and the abscess was 
drained. Repeat CT showed a mediastinal-esophageal fistula with air collections. The latter 
was confirmed at gastroscopy and healed after antibiotic treatment. Results of Gram stains and 
several cultures of EUS and thoracotomy material were negative, as was polymerase chain reac-
tion and culture for Mycobacterium tuberculosis. Four months after the procedure, the patient 
had recovered completely, aside from persistent post-thoracotomy pain.
Case description
The third case concerns an otherwise healthy, 36-year-old man with weight loss and cough. 
On CT, mediastinal and bilateral hilar lymphadenopathy was seen, together with diffuse in-
trapulmonary nodules compatible with stage II sarcoidosis. Subsequently, EUS was performed 
during which enlarged, iso-echogenic, grapelike nodes were observed (15 mm). Two aspirates 
from a subcarinal lymph node demonstrated noncaseating granulomas and abundant bacteria 
(not cultured). Directly after EUS, the patient noticed pain on swallowing, which disappeared 
gradually within 4 days. Six days after EUS, however, symptoms returned and were accompa-
nied by progressive dysphagia but no fever. Inflammatory test parameter results were elevated. 
A CT of the thorax demonstrated enlargement of the subcarinal node from 1 to 3 cm, with 
a central, round, hypodense area compatible with a mediastinal abscess. Esophagoscopy ex-
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cluded an esophageal-mediastinal fistula. The patient was treated with amoxicillin / clavulanic 
acid intravenously for 2 days, followed by oral treatment for 3 weeks, after which all symptoms 
and radiographic changes resolved.
Case description
A 65-year-old woman with a history of eczema and removal of the gall bladder and appendix 
was evaluated for fatigue. A CT scan showed mediastinal lymphadenopathy as well as multiple 
intrapulmonary nodules (sarcoidosis stage II). Conventional bronchoscopy including TBNA of 
a subcarinal node did not yield a diagnosis. Subsequently, EUS was performed, during which a 
subcarinal lymph node was sampled. Cytology showed reactive nodal tissue but no granulomas. 
Ten days after the EUS, the patient developed retrosternal pain and fever (39.9°C).Thirteen 
days after the EUS, the patient presented at the emergency department with persistent high 
fever, right upper abdominal pain, nausea, and pain on breathing. Inflammatory test parameter 
results were grossly elevated, and CT showed a thickened esophageal wall with air collections 
and an enlarged subcarinal node, suspected for an abscess. At gastroscopy, swelling of the 
esophageal wall was observed without signs of an esophageal rupture. The patient was judged 
to be critically ill with threatening sepsis and was transferred to the operating room the same 
day for thoracotomy. A subcarinal abscess was localized, and creamy serous fluid was found in 
the right hemithorax. The abscess and pleural empyema were flushed and drained. Histologic 
nodal resection material confirmed granulomas without necrosis. Blood cultures were positive 
for Staphylococcus aureus, and a pus culture was positive for Streptococcus milleri but negative 
for Mycobacterium tuberculosis. The patient was hospitalized for 22 days, including 5 days in 
the intensive care unit, and she was treated for 6 weeks with intravenous flucloxacillin and oral 
clindamycin. At follow-up, she reported persistent complaints of retrosternal pain and ructus 
without dysphagia, but repeat esophagoscopy showed remission of the esophageal lesions.
Case description
A 57-year-old woman with a history of uterus extirpation, asthma, and melanoma of the skin 
had symptoms of malaise. A CT scan showed multiple, enlarged, mediastinal, and bilateral 
hilar lymph nodes and multiple intrapulmonary nodules (stage II sarcoidosis). At EUS, a sub-
carinal node was aspirated and yielded noncaseating granulomas, consistent with sarcoidosis. 
One week after the procedure, the patient developed fever and retrosternal pressure. Despite 
treatment with antibiotics, symptoms worsened, and the patient developed chills, atrial fibril-
lation, and retrosternal pain, worsening when she was lying flat. Inflammatory test parameter 
results were elevated. A repeat CT scan showed further enlargement of the subcarinal mass, 
with hypodense areas compatible with a subcarinal abscess. A mediastinoscopy was performed 
to drain the abscess. Microbiologic analysis of the purulent material showed species of Entero-
coccus faecium and Streptococcus
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milleri. The patient was treated with amoxicillin / clavulanic acid (2 weeks intravenous, 4 
weeks oral) and recovered fully.
dIsCussIon
We report 5 patients with sarcoidosis (stage I/II) who developed mediastinal abscesses after 
EUS-FNA of subcarinal lymph nodes. Four patients underwent surgery in addition to antibi-
otic treatment. All patients recovered completely.
In recent years, several studies have demonstrated a high yield (> 85%) of EUS-FNA in 
assessing granulomas without necrosis in patients with suspected sarcoidosis.3,4 The occur-
rence of mediastinal infections after EUS-FNA is rare. In the literature, only two mediastinal 
infections have been reported in over 750 sarcoidosis patients undergoing endosonography 
for diagnostic purposes. In 1 patient, the diagnosis of mediastinitis was made, based on blood 
examinations and CT findings, with symptoms resolving after antibiotic treatment.1 The other 
complication is case 2 of the current article, which was reported previously.2 Furthermore, 
mediastinal abscess formation and mediastinitis occasionally have been described in relation 
to EUS-FNA and/or EBUS-FNA in patients with cysts, lung carcinoma, teratomas, or benign 
lymphadenopathy.
Because of its high diagnostic yield for assessing granulomas and very good safety profile, 
EUS is increasingly used as an alternative to bronchoscopy with transbronchial lung biopsies 
to diagnose sarcoidosis. Transbronchial lung biopsies are associated with hemoptysis and 
pneumothorax in 7% of cases.5 In our institutions, 5 of 252 patients with sarcoidosis who 
underwent EUS-FNA for diagnostic purposes developed mediastinal abscesses. These cases are 
retrospective observations from a period of over 10 years in the two institutions. For a proper 
risk assessment of EUS-related mediastinal abscess formation, a prospective complication reg-
istry is indicated. Although all patients fully recovered, the consequences of mediastinal abscess 
formation were severe, because the condition of these patients required prolonged admission, 
intravenous antibiotic treatment, and, most importantly, a thoracotomy. In the 5 specific cases, 
no risk factors such as neutropenia, immunosuppressive therapy, or relevant comorbidities 
were identified.
Both LUMC and Radboud UMC are referral centers for endosonography, and local inves-
tigators have extensive experience in performing endosonography in patients with sarcoidosis 
and lung cancer. In more than 3000 EUS procedures for mediastinal analysis—mostly in lung 
cancer patients—only 2 other cases of mediastinal abscess formation occurred in these two 
centers, both in patients with cystic lesions. Furthermore, because the single-use needle is 
sterile, the scopes were disinfected properly according to manufacturer instructions, and the 
complications occurred in two different centers with many years between the events, the most 
likely cause of the abscess formation is iatrogenic inoculation of the nodes with commensal 
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oropharyngeal flora by the needle. The organisms are introduced through the working channel 
of the scope while it traverses the bacteria-rich oropharynx. Bacteremia after FNA of lymph 
nodes by EUS and EBUS has been reported. In one study, TBNA needle washing results were 
positive for typical commensal oropharyngeal organisms in 35% of cases.6 Despite this, no 
patients developed clinical signs of infection in any of these studies.
It is unlikely that the infectious complications in this case series were caused by one specific 
virulent pathogen, because the cultured bacteria varied and included commensal oropharyngeal 
flora. One might speculate whether abscess formation was caused by a diminished antimicrobial 
response within the lymph nodes. In patients with sarcoidosis, local inflammation is caused 
by increased activation of macrophages and CD4-helper T cells and by increased production 
of cytokines (eg, interleukin-2 and interferon-gamma). Although opportunistic infections are 
uncommon in sarcoidosis,7 a locally increased infection risk may be explained partly by the 
observation that the population of regulatory T cells is amplified at the periphery of sarcoid 
granulomas.8
So far, no mediastinal abscess formation after blind TBNA or EBUS-guided TBNA of medi-
astinal nodes from the airways has been reported. The earlier described complications call for a 
prospective EUS complication registry to properly evaluate whether a potential risk exists from 
diagnosing sarcoidosis by EUS-FNA. In the situation that patients with sarcoidosis are indeed 
at increased risk for developing mediastinal abscesses, the use of prophylactic antibiotic treat-
ment should be discussed. Generally, an optimal yield for finding granulomas can be obtained 
by doing 4 needle aspirations, whereas further attempts do not increase the yield considerably.2 
On-site cytology may limit the risk of complications when granulomas are found after the first 
puncture, and cytological examination may preempt the need for further passes. Aspirating 
inhomogeneous hypo-echoic nodal areas should be avoided, because they often reflect necrotic 
tissue, which could be a risk factor for infections, as described previously.9 Also, rinsing the 
oral cavity with an antiseptic before introducing the endoscope may reduce the chance of an 
infection.
Finally, after EUS, minor complaints such as dysphagia, low-grade fever, coughing, and 
thoracic pain should be taken seriously and followed-up closely. A low-virulence commensal 
pathogen introduced in a mediastinal node may not provoke systemic inflammatory symptoms 
immediately but may progress to a life-threatening infection if left untreated.
We argue, based on these 5 cases, that endoscopists should be aware of this potential com-
plication and register their complications prospectively.
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Endosonography [endoscopic ultrasound (EUS)-guided fine needle aspiration and endobron-
chial ultrasound (EBUS)-guided transbronchial needle aspiration] is increasingly used for 
lung cancer staging and the assessment of sarcoidosis. Serious adverse events (SAE) have been 
reported in case reports, but the true incidence of complications is yet unknown. 
Objectives
To assess the rate of SAE related to endosonography and to investigate associated risk factors. 
Materials and Methods
PubMed, EMBASE and Cochrane libraries were searched for eligible references up to April 
2012 and these included studies reporting on linear EUS or EBUS for the analysis of medias-
tinal/hilar nodal or central intrapulmonary lesions. Case series describing complications were 
excluded. Reported complications were classified
into SAE or minor adverse events (AE). 
Results
190 studies met the inclusion criteria. Information on follow-up was missing in half of the 
studies. In 16,181 patients, 23 SAE (0.14%) and 35 AE (0.22%) were reported. No mortal-
ity was observed. SAE were more frequent in patients investigated with EUS (0.30%) than 
in those investigated with EBUS (0.05%). Infectious SAE were most prevalent (0.07%) and 
predominantly occurred in patients with cystic lesions and sarcoidosis. In lung cancer patients, 
complications were rare.
Discussion
Endosonography for intrathoracic nodal assessment seems safe for lung cancer patients and 
mortality has not been reported. For cystic lesions and sarcoidosis, there may be a small, but 
non-negligible risk of infectious complications.
The true incidence of SAE might be higher as accurate documentation of complications is 
missing in most studies.
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IntroduCtIon
In patients with lung cancer, endosonography is the method of choice for intrathoracic nodal 
staging according to current guidelines1,2. Additionally, it seems the diagnostic method of 
choice for the assessment of sarcoidosis3,4. Several – mainly infectious (mediastinitis/abscess 
formation) – severe adverse events (SAE) have been reported in the literature raising the debate 
on the safety of endosonography5-10 At present, data on the true incidence of endoscopic (EUS)/
endobronchial ultrasonography (EBUS) in routine use are scarce. With the rapid spread of 
novel endosonography techniques, careful monitoring for adverse events (AE) is important.
The aim of the current systematic review was to determine the incidence of SAE attributable 
to the use of endosonography (EUS and EBUS) for intrathoracic investigation and to identify 
subsets of patients who are at risk of developing SAE.
mAterIAls And methods
search strategy
We searched for articles and abstracts mentioning definitive information on complications of 
linear endosonography in the literature for both EUS and EBUS for real-time aspiration of 
mediastinal lymph nodes, and for mediastinal and centrally located intrapulmonary masses. 
An English language systematic literature search (from January 1989 to April 2012) was initi-
ated using PubMed, Cochrane and EMBASE databases which included the following terms: 
‘endosonography’, ‘ebus’, ‘eus’, ‘endoscopic ultrasound’, ‘ultrasound-guided’ combined with 
‘biopsy’, ‘fine-needle’ combined with ‘fine needle aspiration’, ‘fna’, ‘transbronchial needle aspi-
ration’, ‘tbna’ combined with ‘mediastinum’, ‘lung’, ‘respirator’, ‘pulmonary’ and ‘sarcoidosis’.
All initial search results were firstly screened for the eligibility criteria (see below) by one 
investigator (A.v.B.) based on title and abstract. Subsequently, the full article of possibly 
eligible articles was further screened by the same criteria and if indeed eligible, data on the 
type of investigation, study design, sedation, needle size, complications and follow-up were 
documented by two authors (A.v.B. and M.B.v.B.). Articles with complications reported were 
further evaluated by two investigators (A.v.B. and M.B.v.B.). No effort was made to retrieve 
missing data from authors. Any discordance was solved by consensus agreement between all 
three investigators.
eligibility and screening Criteria
Considered for analysis were full-text, prospective and retrospective observational studies as 
well as (randomized) controlled trials and abstracts mentioning information on complications. 
All articles other than original datasets, such as case reports, case series with fewer than 5 
patients, reviews, meta-analyses, duplicates, comments and editorials, were excluded from the 
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analysis. In case no information was mentioned on the rate of complications, these articles were 
also excluded.
Studies assessing the role of EBUS and EUS for indications other than mediastinal or hilar 
lymph node aspirations or central lung masses (e.g. liver, adrenal gland, pancreatic pathology, 
esophageal cancer or duodenal lesions) were excluded. Also, studies of radial or guide-sheath 
EBUS assessing peripheral lung tumors were excluded. Furthermore, studies with patients <18 
years, animals and cadavers were not eligible.
definitions of outcomes
Complications were defined as any AE occurring during and after the procedure and were 
classified into SAE and (minor) AE. An SAE consisted of any AE that was causally related to 
the procedure and was either lethal, could risk the patient’s life, required hospital admission, 
inflicted permanent injury to the health of the patient and/or required intervention to prevent 
permanent impairment or damage11. AE required no hospital admission but did require either 
non- or minimally invasive interventions (e.g. blood oxygen saturation measurement, venous 
puncture or X-ray scanning) and they did not inflict permanent health damage, e.g. nausea, 
vomiting, chest pain, tachycardia, fever <39 °C and minor hemoptysis.
statistical Analyses
The rates of both SAE and AE were calculated dividing the sum of the patients included by 
the number of reported complications. χ2 and Fisher’s exact test were used for the analysis of 
categorical data. All analyses were performed with SPSS (version 17.0).
results
literature search
The search yielded 2,748 references of which 1,776 were excluded after reviewing the title and 
abstract. After reading the full text, a further 782 papers were excluded as they were review 
articles (n = 257), complications were not mentioned (n = 150), they were case reports or 
case series including fewer than 5 patients (n = 149) or they referred to analysis of peripheral 
pulmonary lesions by radial or guided-sheath EBUS (n = 56). Other reasons for exclusion are 
mentioned in figure 1 . A total of 190 articles remained for analysis.
study Characteristics
The 190 articles were published between February 1995 and April 2012. Information on the 
primary indication for EUS/EBUS, the study design and the type of follow-up are listed in 
table 1. EUS-guided fine needle aspiration (FNA) was the method of investigation in 99 stud-
ies (52%), EBUS-guided transbronchial needle aspiration
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(TBNA) was used in 81 (43%), and in 10 articles (5%), both techniques were used. The total 
number of patients investigated was 16,181 (EBUS: 9,119; EUS: 6,042, and both EBUS and 
EUS: 1,020 patients) with a mean of 85 patients per study (range 5–601). Midazolam was used 
as the sedation of choice in 87 studies (46%), general anesthesia in 17 (9%), pethidine in 21 
(11%), propofol in 11 (6%) and other medication or a combination of anesthetics in 12 (6%); 
in 42 studies (22%), the type of sedation was unclear. The needle size used for tissue aspiration 
was 22 gauges in 124 studies (65%), 21 gauges in 7 (4%), 23 gauges in 3 (2%), 19 gauges in 
3 (2%) and 20 gauges in 1 (1%), and a combination of needle sizes was applied in 27 studies 
(14%). Trucut and forceps biopsies were used in 9 (5%) and 3 studies (2%), respectively. In 1 
study (0.5%), no FNA was performed and 24 studies (13%) did not specify needle size.





A total of 23 SAE (tables 2,3) were reported in 36 studies including 16,181 patients, cor-
responding to an SAE rate of 0.14%. Mortality was not reported. In those studies, 35 minor 
AE were observed (0.22%), most of them (28 of 35 AE) were reported in 4 articles. In 151 
studies (79%), no AE were reported and in the remaining 7 (4%) it was stated that there was 
at least no severe complication. 
Eighteen SAE and 25 AE were EUS complications, and EBUS-associated SAE and AE were 
seen in 5 and 10 patients, respectively. No AE were observed in studies combining EUS and 
EBUS. SAE rates for EUS and EBUS were 0.30% (18 in 6,042 patients) and 0.05% (5 in 
9,119 patients), respectively. Of the 23 SAE, 1 (25%) was extracted from a randomized trial 
(n = 4, 246 patients), 12 (11%) were from nonrandomized prospective studies (n = 109, 9,066 
patients) and 10 (13%) were from retrospective studies (n = 77, 6,732 patients). The respective 
SAE rates for randomized controlled trials, and prospective and retrospective designs were 




Randomized trial 4 2 
Nonrandomized trial 186 98 
Prospective 109 59 
Retrospective 77 41 
Indication for EUS/EBUS
Diagnosis and staging of lung cancer 85 38 
Assessment of mediastinal lesions 55 29 
Suspicion of sarcoidosis 12 6 
Suspicion of tuberculosis 3 2 
Mediastinal restaging of extrathoracal malignancies 7 4 
Restaging of lung cancer 5 3 
Diagnosis of mediastinal cysts 2 1 
Diagnosis of lymphoma 1 1 
Various indications 20 11 
Follow-up
Follow-up mentioned 97 51 
Follow-up ≥ 1 month 45 24 
Follow-up ≤ 1 month 33 17 
Follow-up, but no specified length 16 8 
Follow-up of patient complaints 2 1 
No follow-up 1 1 
Follow-up not mentioned 93 49 
Complication Rate of Endosonography (Endobronchial and Endoscopic Ultrasound): A Systematic Review
69
0.41, 0.13 and 0.15%. Of the 23 SAE in all 16,181 patients, 12 (52%) were associated with 
infectious complications, 4 (17%) with perforations of esophageal or pharyngeal structures, 3 
(9%) with respiratory insufficiency, 2 (9%) with a pneumothorax and 2 (9%) with a puncture-
related hemorrhage. Severe complications occurred in 8 patients with lung cancer (35%), in 
5 with mediastinal cysts (22%), in 3 with sarcoidosis (13%), in 2 with tuberculosis (9%), in 
1 mesothelioma (4%) and in 1 benign lymphadenopathy patient (4%). In the remaining 3 
patients (13%), the indication for endosonography was unclear.
There were no reports of SAE-induced persistent impairment in the patients. Outcomes 
were reported as full recovery (n = 11), unclear (n = 1) and no information was given on the 
outcome in the remaining patients (n = 11).
severe adverse events
Infectious complications
Five patients had a diagnosis of mediastinitis and 3 had mediastinal abscess formation (tables 
2,3). Three of those were in patients with a final diagnosis of a mediastinal cyst. Two patients 
underwent Trucut biopsy of a mediastinal mass. The first was a 52-year-old man referred for 
evaluation of a bulky lower mediastinal mass. Six earlier passes with EUS-FNA yielded no 
definitive diagnosis so 3 Trucut biopsies were obtained. Two days later, the patient presented 
table 2. Overview of SAE following EUS-FNA (n = 6,042) and EBUS-TBNA (n = 9,119) for mediastinal analysis 
(n = 23)
Infectious complications (n=12) EUS (n=18) EBUS (n=5)
Mediastinitis 10 2
Mediastinal abscess/abscess formation 5 0 
Sepsis 2 1 
Pleuropericarditis 1 1 
Aspiration pneumonia 1 0 
Perforations (n=4) 1 0 
Esophageal perforation/rupture 3 0 
Sinus piriformis perforation 1 0 
Pneumothorax (n=2) 0 2
Hemorrhagic complications (n=2) 2 0
Mediastinal hematoma 1 0 
Periesophageal bleeding 1 0 
Respiratory complications (n=3) 2 1
Hypoxemia due to airway edema 1 0 
Apnea under propofol 0 1 
Required reversal medication 1 0 
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with complaints of dysphagia and chest pain. CT scanning showed an image compatible with 
mediastinitis. During thoracotomy, an 8-cm cystic lesion with purulent drainage arising from 
the distal esophagus was excised. The patient recovered uneventfully and was discharged after 
8 days. The other patient developed severe sepsis secondary to mediastinitis 4 days after EUS-
FNA. Thoracotomy was indicated and revealed an infected bronchogenic cystic abscess. The 
third patient had a lymph node abscess following EBUS-TBNA of a subcarinal cystic metastatic 
lymph node, but it resolved after antibiotic treatment. One patient with non-small cell lung 
cancer (NSCLC) and brain metastases developed mediastinitis after an iatrogenic esophageal 
perforation due to technical problems with the needle. He was treated with antibiotics, dis-
charged 25 days after the procedure and died 6 days later due to progression of his malignancy. 
Another patient with a left upper lobe tumor and an enlarged, necrotic-appearing subcarinal 
lymph node underwent 4 FNA which yielded small cell carcinoma. Two days after EUS, he 
developed fever. Without an evident focus for the fever, he was given empiric antibiotic treat-
ment, only to return 2 days later with persistent fever and elevated inflammatory parameters. 
CT scanning showed air bubbles in the subcarinal area for which intravenous antibiotics were 
started. After 1 week, the inflammatory parameters normalized and the patient was treated 
with concurrent chemoradiotherapy.
One patient with sarcoidosis underwent diagnostic FNA with a 19-gauge needle to obtain tis-
sue proof of noncaseating granulomas. He complained of chest pain the day after the procedure 
and was diagnosed with mediastinitis based on blood examination as well as CT findings. His 
symptoms resolved during the 1-week treatment with antibiotics. Another sarcoidosis patient 
developed retrosternal pain and fever 2 days after EUSFNA of subcarinal and paratracheal 
lymph nodes but only reported 10 days after developing symptoms. CT images showed local 
abscesses in the biopsied area. Following necrotic nodal tissue removal during thoracotomy, 
the patient completely recovered. The last patient with a mediastinal abscess was a patient 
with a 4-month history of hoarse voice and weight loss undergoing EUS-guided Trucut biopsy 
for tissue analysis of a paratracheal mass with echographic features suggestive of necrosis. 
Three days later, she presented with dysphagia and pyrexia, and CT revealed peritracheal 
and retroesophageal collections. Cervical drainage revealed pus. Initial EUS Trucut biopsy 
histology demonstrated histiocytic granulomas, which were culture positive for Mycobacterium 
tuberculosis.
One procedure in a patient undergoing 22-gauge EUS-FNA for suspicion of a mediastinal 
cyst was complicated by a pleuropericarditis and atrial fibrillation. Treatment involved pleural 
drainage over a 21-day hospitalization.
Two patients developed sepsis. In 1 patient, puncture of a mediastinal cyst led to a septic 
complication, for which the patient was treated surgically. Another patient was scheduled 
for EBUS-TBNA to assess a right paratracheal lymph node. Four uncomplicated passes 
yielded necrotizing granulomas also positive on Ziehl-Neelsen staining. Under antituberculous 
therapy, the patient presented with sepsis 2 days after the procedure and blood cultures showed 
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β-hemolytic group G streptococci. He improved with antibiotic treatment and was discharged 
after 6 days without further complications.
Finally, 1 patient was hospitalized after the procedure for aspiration pneumonia secondary to 
periprocedural aspiration of blood. The patient’s condition improved with supportive care and 
intravenous antibiotics; the patient was discharged 48 h later.
Gastrointestinal Perforations and Pneumothoraces
Four perforations (3 esophageal and 1 sinus piriformis) related to EUS-FNA occurred on top 
of the one already mentioned above. One patient with mesothelioma was referred for surgical 
correction of an esophageal perforation and was discharged from hospital after several weeks. 
Another patient developed an esophageal perforation due to technical failure; he was treated 
with antibiotics and discharged 6 days after EUS-FNA in good clinical condition without 
developing an infectious complication. Furthermore, rupture of the esophageal wall occurred 
in 1 case because of improper use of the sheath of the needle. After the lesion was clipped, the 
patient’s clinical course was uneventful. The remaining patient had swallowing problems and 
a large goiter. He was referred for analysis of mediastinal lymphadenopathy, and during EUS, 
rupture of the sinus piriformis was encountered due to difficulty in scope introduction. After 
administration of intravenous antibiotics, the patient recovered uneventfully.
Two patients undergoing EBUS-TBNA for diagnosis and staging of NSCLC developed 
a pneumothorax: 1 patient after FNA of a lung lesion and the other after aspiration of a 
mediastinal node. Both required chest tube drainage.
Other Severe Complications
Two patients had a complication involving mediastinal hematomas. One complained of pain 
after Trucut core biopsy of a benign subcarinal node. The bleeding was detected during EUS 
and the patient was observed for 3 days in the hospital and treated with intravenous narcotics 
for pain management. No significant drop in hemoglobin was seen. A CT scan showed a peri-
esophageal hematoma but no intervention was necessary. The other patient had a mediastinal 
hematoma after EUS-FNA resolving after a conservative treatment of fasting and bed rest. 
One procedure was complicated by respiratory failure in a patient undergoing mediastinal 
EUS through the upper gastrointestinal tract under propofol sedation. He required transient 
endotracheal intubation but did not require hospitalization overnight. Another developed 
stridor and hypoxemia due to airway edema causing early termination of the procedure. A 
final patient required reversal medications, but no further information was given for this AE.
Adverse Events
A total of 35 minor complications were reported in the papers analyzed. During the examina-
tion in 4 EBUS patients, a small bleeding occurred at the puncture location, requiring instil-
lation of 1 mg noradrenaline to stop the bleeding in 3 patients; in 1 patient the procedure 
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was terminated but the bleeding stopped without intervention. In 4 EUS patients, a small 
peri- or intranodal extravasate was seen on ultrasound images after nodal aspiration, but nei-
ther of them required intervention. In 1 patient, respiratory depression with apnea occurred. 
Abortion of the procedure resulted in full recovery. In another patient, nodal aspiration could 
not be performed due to intraprocedural oxygen desaturation. One patient developed stridor 
immediately after an EUS procedure, but no intervention was necessary. Two cases of atrial 
fibrillation (1 EUS and 1 EBUS procedure), 1 case of tachycardia (>150 bpm) and 1 case of 
hypotension were also described: all were self-limiting. In 1 patient, an EBUS procedure had 
to be terminated due to severe coughing preventing continuation of the procedure. In 1 case, 
introduction failed due to unspecified reasons.
Four patients complained of pain after an EUS procedure. Two patients developed severe 
chest pain and 2 had abdominal pain. The cause of pain could not be found in all patients 
whereupon they were discharged with conservative treatment with pain medication. Six pa-
tients complained of a self-limiting sore throat after EUS. Post-procedural fever was seen after 
2 examinations. Both received prophylactic antibiotics although no infectious focus was found. 
Moderate-grade pneumomediastinum with complication- free regression was found in 1 case 
after a Trucut needle biopsy. Self-limiting nausea with vomiting in 2 patients and intractable 
coughing, hemoptysis and pain on swallowing in 3 other patients were furthermore reported.
dIsCussIon
This systematic review shows that the reported complication rate of EUS and EBUS is low 
with an SAE rate of 0.14%. Fatalities associated with EUS/EBUS have not been described nor 
have been cases of persistent impairment. Follow-up of patients for possible complications is 
often not routinely performed, and a lack of documentation may have underestimated the rate 
of SAE and particularly for minor AE, which are seldom reported. SAE as described in the 
literature as case reports5-10 do occur but are rare with an overall rate of 0.14% and are mostly 
infectious complications such as mediastinitis and mediastinal abscess formation, which are 
both severe and potentially life-threatening AE.
Regarding the high number of articles including patients with (suspected) lung cancer and 
the low prevalence of lung cancer-associated SAE, it seems that EUS and EBUS are safe tech-
niques for an intrathoracic investigation of the mediastinum in these patients. Only 2 cases of 
severe infectious complications have been described in lung cancer patients yet; one was due 
to technical problems and the other had necrotic lymph nodes. It has been suggested earlier 
by Aerts et al.5 that the presence of necrosis in patients with mediastinal nodal metastases of 
small cell lung cancer could be a risk factor for developing mediastinal infections due to avas-
cularity of the lesion. We argue that in case of suspected tissue necrosis (e.g. inhomogeneous 
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hypoechoic nodal areas on echographic images), the investigator should avoid puncturing of 
these specific areas and minimize the number of aspirations.
The low complication rate found corresponds with the low incidence of complications in 
the three largest meta-analyses of EUS and EBUS reported in the literature 12-14. In addition, 
the risk of developing a pneumothorax requiring chest drainage after EBUS is small with only 
2 cases reported, therefore obviating the need to routinely perform chest X-rays after EBUS-
TBNA, which is also reflected by a study reporting on puncturing lung lesions in 60 patients, 
in which pneumothorax was not once reported15.
Regarding infectious SAE, there are probably specific patient groups at risk, e.g. a large part 
of these AE occurred in patients with cysts and sarcoidosis. The risk of aspirating cystic lesions 
is apparent considering the relatively low prevalence of mediastinal cysts in general and the 
documented number of mediastinal infections following cyst aspiration. Cystic lesions are also 
avascular, and an inoculation of bacteria into the cyst most likely leads to local uninhibited 
bacterial growth due to the inability of the immune system to reach and fight the pathogens 
there. In case of a suspected mediastinal cyst based on ultrasound features, needle aspiration 
of the cyst (e.g. anechoic appearance on echography) should certainly be avoided10. Wildi et 
al.10 reported tissue sampling in mediastinal cysts in 4 patients, and in 3 of them prophylactic 
antibiotics were administered. Only in the patient receiving no antibiotics a mediastinal infec-
tion developed. In our retrospective case series9 of patients with sarcoidosis, patients had an 
increased risk of developing mediastinal infection following nodal puncture, perhaps due to an 
impaired antimicrobial response within the lymph nodes. Whether a true increased risk exists 
should be further investigated in a large prospective evaluation. Until then, endoscopists should 
be aware of this potential complication in patients with sarcoidosis and consider administering 
prophylactic antibiotic treatment.
There was a difference in the amount of SAE between EUS and EBUS in favor of EBUS, 
but the reason for this discrepancy is not entirely clear. Because infectious complications are 
rare with EBUS, it may be that inoculation of gastrointestinal tract bacteria in mediastinal 
lesions or masses offers an increased infection risk as opposed to the large airways, which are 
less abundant in commensal flora. On the other hand, the rate of infectious complications 
in a recent Japanese nationwide survey of EBUS-TBNA was quite comparable to the rate of 
infectious SAE of EUS-FNA in our review of the literature (0.19 vs. 0.17%)16.
This review shows that incidental perforation of the gastrointestinal tract (5/6,042; 0.08%) 
may occur due to endoscopic investigation, but the data do not suggest a heightened incidence 
of such AE compared to the rate of perforations for esophagogastroduodenoscopy (0.03%)17. 
In the literature, the risk of peri- or postprocedural hemorrhage (0.01%) seems lower than that 
in the survey of Asano et al.16 (0.68%), for instance, but this may be attributable to reporting 
bias; minor bleeding at the puncture site is often observed, but seldom requires intervention.
There are several limitations to this study: some pertain to our study design and the others 
to the quality of the studies included. We did not screen articles twice; therefore we may have 
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missed or falsely included studies. Secondly, we did not fully register all reasons for possible 
study exclusion in our systematic review. Although this may have offered a very informative 
insight, it means we do not know exactly how many studies did not report on complications.
Concerning limitations of the studies included, first of all, most prospective studies had a 
focus on efficacy of the diagnostic techniques and not on complications. Secondly, information 
on the occurrence of complications is not always dispensed in the articles we analyzed. For one 
part, some articles (that were excluded before the final analysis) did not report at all whether 
AE had occurred. For the other part, in the papers that did report on the occurrence of AE/
SAE, a follow-up period was not mentioned or specified in half of the patients. Complications 
such as bleeding will present immediately during or following endosonography, but others, 
such as infectious complications, develop over time. The lack of an accurate follow-up may 
have excluded these AE, which results in an underestimation of the SAE rate. Also, a consider-
able part of patients undergoes further investigations, such as mediastinoscopy or thoracotomy, 
shortly after a negative EUS/EBUS. Inadequate follow-up may have falsely attributed AE to 
these techniques instead of endosonography.
In general, severe complications and those with fatal outcomes are subject to publication 
bias and may have remained unpublished. Certainly, the low number of minor complications 
(0.22%, nearly as low as 1 in every 500 patients) is not reflecting current practice. Almost no 
minor AE have been reported although complaints of hemoptysis, sore throat or intractable 
coughing are common. Finally, it would be interesting to stratify the complication rate ac-
cording to specific disease conditions of patients, but unfortunately information on the final 
diagnoses was often not available.
In conclusion, it seems that endosonography is a safe technique for intrathoracic assessment 
of the mediastinum. Mortality has not been reported and SAE in patients with lung cancer are 
very rare. The true incidence of SAE may be higher, possibly due to the lack of communication 
on complications. For sure, the rate of minor AE is severely underestimated. Better monitoring 
of (severe) adverse events is advised. This pertains especially to patients with sarcoidosis in 
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Endosonography is being implemented rapidly in pulmonary medicine for the diagnosis and 
staging of lung cancer, the assessment of sarcoidosis, and the assessment of mediastinal lesions. 
Although serious adverse events (SAEs) have been described, safety data outside cohort studies 
are scarce.
Objective
To assess the SAE and mortality rate of EUS-guided FNA (EUS-FNA) and endobronchial 
ultrasound guided transbronchial needle aspiration (EBUS-TBNA) for mediastinal and/or 
hilar analysis.
Design
Nationwide, retrospective survey by using questionnaires.
Setting
All hospitals in the Netherlands.
Patients





Occurrence of fatal outcomes and SAEs. Detailed information was obtained for each reported 
case, and all cases were reviewed independently by 2 investigators, including identification of 
risk factors.
Results
All 89 hospitals (100%) responded. An estimated 14,075 EUS-FNA and 2675 EBUS proce-
dures were performed. Seven patients died after endosonography (5 EUS-FNA, 2 EBUS [mor-
tality rate 0.04%]). All fatalities occurred in patients of poor performance status (American 
Society of Anesthesiologists Physical Status Classification System score of III/IV). Twenty-five 
SAEs were reported (22 EUS-FNA, 3 EBUS [SAE rate of 0.15%; EUS-FNA 0.16%, EBUS 
0.11%]). SAEs were mostly (64%) of infectious origin. No specific risk factors for infectious 
adverse events could be identified.
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Limitations
Retrospective study, possible recall bias, overrepresentation of EUS-FNA cases.
Conclusion
Endosonography appears to be a safe technique for the analysis of mediastinal and/or hilar le-
sions. Poor performance status is a risk factor for fatal outcomes. Mediastinitis and/or mediasti-




Endosonography (EUS-guided FNA [EUS-FNA]) and endobronchial US–transbronchial 
needle aspiration (EBUS-TBNA) is an increasingly used diagnostic technique in patients in 
whom tissue verification of intrathoracic lymph nodes is indicated for the diagnosis and staging 
of lung cancer, the assessment of sarcoidosis, or the analysis of mediastinal masses.
Lung cancer staging guidelines recommend endosonography as the initial tissue staging 
test after CT or positron emission tomography (PET) to detect mediastinal node disease.1 
Subsequent surgical staging is indicated in those patients with suspected node involvement in 
whom endosonography did not find metastases. For the detection of granulomas in patients 
with suspected sarcoidosis, endosonography is superior to conventional bronchoscopic tech-
niques.2,3 The large body of evidence regarding the use of endosonography-guided mediastinal 
node aspiration4,5 results in rapid implementation. With over 1.8 million new cases of lung 
cancer worldwide each year6 and an estimated prevalence of sarcoidosis ranging from 1 to 40 
cases per 100,000 population,7 it is expected that several hundreds of thousands of mediastinal 
endosonography procedures will be performed annually. Besides diagnostic test characteristics, 
safety and adverse events of novel techniques are of major importance. In a recent literature 
review, few serious adverse events (SAEs) after endosonography were reported.8 However, 
SAEs have been described in several case reports,9-14 including suggestions of endosonography-
associated fatalities.15,16 In the current implementation phase of endosonography, insight into 
SAEs, including identification of risk factors, is important. However, data on safety outside of 
clinical trial settings are scarce.
Therefore, we conducted a nationwide, retrospective survey of all mortality and SAEs related 
to EUS-FNA and EBUS procedures performed in the Netherlands over a 12-year period.
mAterIAls And methods
data collection
We conducted a nationwide survey by sending questionnaires to all 89 hospitals (both per-
forming and referring EBUS/EUS-FNA centers) in the Netherlands during 2010 to 2011. The 
questionnaires requested that respondents report SAEs. One questionnaire was designed for 
those clinics performing EUS-FNA and/or EBUS, the other for those referring patients for the 
procedures. In case SAEs were reported, additional detailed information including endoscopy 
and radiologic reports as well as relevant medical correspondence was obtained.
definitions of outcomes
All fatal outcomes and SAEs were assessed independently by the two physicians and classified 
according to severity of the adverse events according to Common Terminology Criteria for 
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Adverse Events (CTCAE) (Table 1).17 All events were discussed, and the treating physician was 
consulted in case further clarification was indicated.
SAEs were defined as adverse events threatening the health of the patient, either concern-
ing an active problem requiring intervention to avert further damage (e.g., severe infection, 
esophageal laceration) or an unforeseen event causing no harm in this particular case but 
having serious potential to do so (eg, mediastinal hematoma). SAEs were subdivided into 
grades 2, 3, 4, or 5 by using the CTCAE grading scale and included death, mediastinitis, 
bleeding, severe respiratory failure, perforation, empyema, and equipment misuse as well as 
adverse events that may lead to clinical deterioration such as drug intoxication or aspiration. 
An invasive intervention was defined as any procedure in which there was a break in the skin or 
there was contact with the mucosa or any internal body cavity. These included surgery, pleural 
drainage, gastroscopy, and so forth. A noninvasive or minimally invasive intervention included 
investigations such as blood oxygen saturation, venous puncture, or radiographic scanning. A 
hospital admission was defined as at least an overnight stay.
statistical analysis
SAEs and mortality rates of EUS-FNA and EBUS were calculated by dividing the sum of 
adverse events by the average of the sum of the lower and upper limits of the reported estima-
tions of performed procedures. The Chi-square and Fisher exact tests were used for the analysis 
of categorical data. All analyses were performed with SPSS (version 17.0, Chicago, Ill, USA).
table 1. Severity score of E(B)US related adverse events
severity grade
Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated 1 
Moderate; minimal, local or noninvasive intervention indicated 2
Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of 
hospitalization indicated
3
Life-threatening consequences; urgent intervention indicated 4
Death related to adverse event 5
E(B)US was judged as an contributing factor to the fatal outcome A
E(B)US was judged as the major cause of the fatal outcome B 
In addition to the CTCAE classification, we subdivided death (grade 5) into death accelerated by EBUS (A) and 
death as a direct result of EBUS (B). 




Completed questionnaires from all 89 Dutch hospitals were collected. Forty-three of 89 clinics 
(48%) performed endosonography (EUS-FNA alone 21%, EBUS alone 1%, both EBUS and EUS-
FNA 26%). An estimated 16,750 procedures were performed (14,075 EUS-FNA, 2675 EBUS).
Seven cases of endosonography-associated fatal outcomes (5 after EUS-FNA, 2 after EBUS) 
and 65 SAEs were reported. Eleven identical SAE cases were reported by both the executing and 
referring centers. One patient was reported to present with a sinus arrhythmia and another with 
chest pains, but these both proved to be pre-existent after further analysis. In 3 patients who had 
respectively developed mediastinitis, a pulmonary embolism, and bleeding >50 mL after EUS, 
the outcome could not be evaluated because the reporting physicians remembered the events 
but could not identify or retrieve the individual case records. A further 24 cases were excluded 
for final analysis because they were deemed adverse events and not SAEs. These cases concerned 
18 patients with minor nodal extravasation (16 EUS-FNA, 2 EBUS), 3 patients with fever 
after the procedure (1 EUS-FNA, 2 EBUS), and 3 patients with minor aspiration after heavy 
coughing (1 EUS-FNA, 2 EBUS), none of whom required intervention or hospital admission.
Thereby, 25 SAEs (22 after EUS-FNA, 3 after EBUS) were included in the final analysis. 
Most of these were of infectious origin (N = 16. 64%). Based on the estimated number of 
procedures performed, the overall mortality rate of endosonography was 0.04% [7/16.750; 
EUS 0.04%, 5/14.075; EBUS 0.07%, 2/2.675] and the SAE rate was 0.15% [25/16.750; EUS 
0.16%, 22/14.075; EBUS 0.11%, 3/2.675]. For infectious adverse events these figures were 
0.10% [16/16.750] (EUS, 0.10% [15/14.075]; EBUS 0.04% [1/2.675]).
fatal outcomes after endosonography
Seven patients died after EUS-FNA (n = 5) or EBUS (n = 2) (Table 2). Four patients (3 
EUS-FNA, 1 EBUS) most likely died as a direct result of endosonography, and in 3 patients (2 
EUS-FNA, 1 EBUS) the endosonography procedure was judged to have been a contributing 
factor that influenced the fatal outcome.
Case description 
An 81-year-old woman with suspected stage III non-small cell lung carcinoma underwent 
EUS-FNA for staging purposes, with sampling of a left-sided, paratracheal node. The procedure 
was complicated by a difficult endoscope introduction. Immediately after the procedure, the 
patient reported severe back pain and shortness of breath. The next day, a pneumothorax was 
detected as well as an esophageal perforation—proven by both barium swallow and gastroscopy. 
That same day she developed a high fever, and the diagnosis of mediastinitis and sepsis was 
made. Because of locally advanced lung cancer (confirmed by the EUS-FNA), her advanced 
age, and her rapidly deteriorating clinical condition, no antibiotic or surgical treatment was 
initiated, and she died 2 days after EUS.
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Case description
A 51-year-old man with nonspecific interstitial lung lesions and mediastinal lymphadenopathy 
underwent EUS-guided aspirations of left-sided, paratracheal (station 4L) and subcarinal 
(station 7) nodes, demonstrating undifferentiated non-small cell lung carcinoma compatible 
with locally advanced (stage IIIB) lung cancer. Nine days after EUS-FNA, he presented to the 
emergency department with fever, and a subsequent CT scan of the chest showed increased 
mediastinal node enlargement with air bubbles—new in comparison to the scan before endos-
copy—as well as pleural empyema. On the diagnosis of mediastinitis and empyema, antibiotic 
treatment with amoxicillin/clavulanic acid was started (with steroids for the interstitial lung 
disease), and thoracic chest tube drainage was performed, complicated by pneumothorax. Sev-
eral days after admission, the patient’s clinical condition deteriorated, necessitating intensive 
care unit admission, including invasive ventilation. After extubation and transfer to a recovery 
unit, he failed to recuperate and thereupon was referred to an academic center for invasive 
drainage of the mediastinum by thoracotomy. Despite surgical evacuation, chest tube drainage, 
and Augmentin and fluconazole treatment (Candida was cultured), the patient’s clinical condi-
tion further deteriorated, and he died 4 weeks after EUS-FNA. 
Obduction demonstrated sarcomatoid large cell undifferentiated carcinoma with signs of 
mediastinitis. The alveoli of the lungs were diffusely damaged, probably by sepsis, leading to 
respiratory failure. Culture of the empyema showed Streptococcus constellatus.
Case description
A 64-year-old man with type II diabetes underwent an uneventful EUS-FNA for suspected 
stage IIIA non-small cell lung carcinoma with aspirations at nodal stations 4L and 7. Several 
hours after the procedure, retrosternal pain occurred, followed by fever 4 days later. A CT 
table 2. Fatal outcomes (mortality) after EUS-FNA and EBUS-TBNA related to indications, intervention type, 







Barium swallow X-ray, pleural drainage
grade
5B
Mediastinitis EUS-FNA Thoracotomy, thoracic drains, IV antibiotics, ICU admittance, 
invasive ventilation 
5B
Mediastinitis / empyema EUS-FNA Thoracotomy, thoracic drains, IV antibiotics, ICU admittance, 
invasive ventilation
5B
Heart failure EUS-FNA Cardiopulmonary resuscitation 5A
Respiratory failure EUS-FNA Doxapram, non-invasive ventilation, ICU admittance 5A
Pneumosepsis EBUS-TBNA Antibiotics, ICU admittance, invasive ventilation 5B
Pneumosepsis EBUS-TBNA Antibiotics, ICU admittance, invasive ventilation 5A
All indications for EBUS were non-small cell lung carcinoma.
EUS-FNA, EUS-guided FNA; EBUS-TBNA, endobronchial US–transbronchial needle aspiration; IV, intrave-
nous; ICU, intensive care unit.
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scan of the chest suggested mediastinitis, which was confirmed at thoracotomy, during which 
a right-sided pneumonectomy (histopathological diagnosis [PA]: pT4N2M0 adenocarcinoma 
right upper lobe) and abscess drainage were performed. Initial recovery was favorable, but 
the patient returned 1 month after discharge to the emergency department with symptoms 
of coughing and fever. CT images then showed right-sided pleural empyema in the pneu-
monectomy space and bilobar pneumonia in the left lung. Despite antibiotic treatment and 
later intubation, the patient’s clinical condition deteriorated quickly, and he died because of 
respiratory failure.
Case description
A 71-year-old man presented with chronic obstructive pulmonary disease (COPD) stage III to 
IV, obstructive sleep apnea, and extensive aortic valve disease (both regurgitation and stenosis). 
An EUS-FNA was performed for analysis of a subcarinal node in suspected stage IIIA, N2 
non-small cell lung carcinoma. Before introduction of the endoscope, 5 mg of midazolam was 
administered. Oxygen saturation dropped immediately until it reached 78%, for which oxygen 
(5 L/minute) and flumazenil were given, resulting in oxygen saturation of 95%, after which 
an uncomplicated EUS-FNA was performed, demonstrating metastatic adenocarcinoma. 
Two hours later, the patient’s level of consciousness dropped, and blood gas analysis showed 
severe hypercapnia (>13 kPa). Despite conservative treatment with noninvasive ventilation 
and doxapram, he developed pulmonary edema. Because of his prognosis and comorbidities, 
the treating physicians refrained from invasive ventilation, and he died several hours after 
EUS-FNA because of respiratory insufficiency.
Case description
A 70-year-old woman presented with significant medical history including COPD (Global 
Initiative for Obstructive Lung Disease grading system grade III), two-vessel coronary artery 
disease, myocardial infarction, and left ventricular hypertrophy. Two months before EUS-FNA, 
the patient underwent a lobectomy for a cT2N1 adenocarcinoma of the right upper lobe in 
combination with a coronary artery bypass graft procedure. The operation was complicated by 
a sternal wound infection, COPD exacerbation, and pneumonia. The patient was resuscitated 
after a cardiac arrest following respiratory insufficiency caused by exacerbation of the COPD, 
further aggravated by opiate intoxication. During recovery, the patient fell in the hospital, 
and on subsequent radiographic imaging of the humerus a suspected pathological fracture was 
observed. PET scanning showed humeral uptake as well as hot spots in the sacrum and the 
left adrenal gland. To confirm M1 disease, an EUS-FNA was scheduled, and two transgastric 
left adrenal aspirations were performed. The patient was premedicated with local lidocaine 
spray and 2.5 mg of midazolam. During the EUS-FNA, low oxygen saturation levels were 
observed, for which oxygen (5 L/minute) and flumazenil were administered. EUS-FNA aspira-
tions confirmed metastatic non-small cell lung carcinoma disease in the adrenal gland. After 
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endoscopy the patient was well awake and oriented, but during the night she was found in an 
unresponsive state and she succumbed after unsuccessful resuscitation. Besides metastasized 
adenocarcinoma, autopsy showed extensive pulmonary edema in addition to the preexistent 
COPD, left ventricular hypertrophy, and cardiac ischemia. Most likely, endosonography had 
induced fatal heart failure in this patient of frail health.
Case description
A 52-year-old woman with COPD (GOLD system grade III) was referred for EBUS-TBNA 
for tissue confirmation of mediastinal recurrence of T3-4N2M0 adenocarcinoma after 7 years. 
She presented with a 4-cm, right-sided, central mass, with two PET-positive mediastinal nodes. 
One day after an uncomplicated EBUS with TBNA of a right paratracheal node showing nor-
mal nodal tissue without malignancy, the patient had fever and chills for which she was treated 
with broad-spectrum antibiotics and steroids on the presumed diagnosis of pneumonia with an 
obstructed right main bronchus. Because of increasing hypercapnia, the patient was transferred 
to the intensive care unit and intubated, but her condition deteriorated further, and treatment 
was terminated. She died because of hypercapnic respiratory failure after pneumosepsis, 16 
days after EBUS.
Case description
A 65-year-old woman had a large, central, necrotizing, lung tumor with endotracheal necrotic 
abnormalities and right-sided enlarged paratracheal and hilar lymph nodes, suspicious for me-
tastases. The patient underwent EBUS-TBNA for staging purposes. Immediately after TBNA, 
a small, local, endobronchial bleeding episode was observed. Because the oxygen saturation 
dropped to 72%, the procedure was terminated. Two days after EBUS, the patient was read-
mitted, presenting with (postobstruction) pneumonia and a small pleural effusion. Despite 
treatment with clindamycin, ciprofloxacin, and furosemide, her clinical status worsened, and 
she died 2 days after admission.
non-fatal sAes after endosonography
Infectious adverse events
Sixteen cases of non-fatal infectious adverse events were reported after endosonography (Tables 
3 and 4). Thirteen patients were diagnosed with a severe mediastinal infection—6 with me-
diastinitis (all after EUS-FNA) and 7 with a mediastinal abscess (6 after EUS-FNA, 1 after 
EBUS). Of those, 7 had to undergo surgery (6 thoracotomy, 1 mediastinoscopy) in addition 
to prolonged antibiotic treatment. In addition, 1 patient presented with pleural empyema 
(EUS-FNA), 1 with aspiration pneumonia (EUS-FNA), and 1 with mediastino-esophageal 
fistula (EUS-FNA). Cultures were available for 6 of 7 patients undergoing surgery and showed 
varying cultures of Streptococcus milleri (3x), Streptococcus viridans, Streptococcus salivarius, 
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Staphylococcus aureus (2x), Candida albicans, Enterococcus faecium, Actinomyces, and Mycobacte-
rium tuberculosis for a patient with a tuberculosis fistula.
Including the fatal infectious outcomes, the clinical course could be reconstructed in detail 
in 17 of 21 patients with an infectious adverse event. In most cases (14/17, 82%) patients 
presented with symptoms of fever after a mean of 4.8 days after EBUS (range 1-15). In the 
other cases, symptoms of dysphagia (n = 2) and thoracic pains (n = 1) developed after 6, 2, and 
2 days, respectively.
table 3. Serious adverse events after EUS-FNA stratified for indications and type and graded according to the 
severity scale (Table 1)
Adverse event Indication for eus Intervention after eus grade
1* Mediastinitis Cyst Thoracotomy, IV antibiotics 4
2 Mediastinal abscess Cyst Thoracotomy, IV antibiotics 4
3* Mediastinal abscess Sarcoidosis Thoracotomy, IV antibiotics 4
4* Mediastinal abscess Sarcoidosis Thoracotomy, gastroscopy, IV antibiotics 4
5* Mediastinal abscess Sarcoidosis Mediastinoscopy, IV antibiotics, 4
6* Mediastinal abscess Sarcoidosis Gastroscopy, thoracotomy, ICU 
admittance IV antibiotics
4
7 Mediastinitis NSCLC IV antibiotics 3
8* Mediastinal abscess Sarcoidosis Gastroscopy, IV antibiotics 3
9 Mediastinitis / esophageal laceration NSCLC IV antibiotics 3
10 Mediastinitis / esophageal laceration Sarcoidosis IV antibiotics 3
11 Mediastinitis NSCLC IV antibiotics 3
12* Mediastinitis SCLC IV antibiotics 3
13* Mediastino-esophageal fistula Tuberculosis Gastroscopy, antibiotic + tuberculostatic 
agents
3
14 Pleural empyema Contamination from 
gastric tube 
IV antibiotics, drainage 3
15 Aspiration pneumonia Mediastinal analysis Antibiotics 3
16 Pneumomediastinum / thoracal pains NSCLC CT, IV antibiotics 3
17 Pneumomediastinum / emfysema 
cutis
Sarcoidosis CT, two days admittance 3
18 Esophageal laceration Mediastinal analysis Several days admittance 3
19* Sinus piriformis perforation NSCLC Barium swallow X-ray; several days 
admission, antibiotics
3
20 Pneumothorax NSCLC Pleural drainage, 2 days admission 2
21 Emfysema cutis NSCLC Chest X-ray, clinical follow-up 2
22 Esophageal ulcer Sarcoidosis Gastroscopy; no further intervention 2
EUS-FNA, EUS-guided FNA; IV, intravenous; ICU, intensive care unit; NSCLC, non-small cell lung carcinoma.
*Adverse events with an asterisk were published before.
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Other adverse events
Bleeding adverse events were reported in 3 patients. One patient had a self-limiting hemor-
rhage of approximately 150 mL after EBUS-TBNA of a centrally located intrapulmonary lung 
lesion. Most likely the arteria pulmonalis sinistra was accidentally punctured when an attempt 
was made to sample a central mass in the left lung. This patient required monitoring for 4 
hours.
Two patients presented with pneumomediastinum. One 68-year-old woman with right-sided 
non-small cell lung carcinoma and diffuse pulmonary and mediastinal metastases underwent 
an uncomplicated EUS-FNA, but within hours after the procedure she developed extremely 
sharp pains between the shoulder blades. CT showed air around the esophagus without 
pneumothorax or hematoma formation. She was treated with nasogastric suction, intravenous 
amoxicillin/clavulanic acid, and fluid administration which was done for 2 days.
A 29-year-old woman with suspicion of sarcoidosis stage II underwent unsuccessful intro-
duction under midazolam. Thirty minutes after EUS-FNA, she developed emphysema cutis of 
the face and neck. CT scanning was positive for very extensive local subcutaneous emphysema, 
also found around the back and shoulders, larynx, proximal esophagus, and mediastinum as 
well as intrapleurally (with normally expanded lungs) and intraperitoneally around the liver 
and intestines. No clear perforation was seen on CT. The patient was hospitalized for several 
days.
Another patient presented with a laceration of the esophagus, which required a short admis-
sion but no further treatment.
Furthermore, after difficult introduction of the endoscope, a patient with a large goiter 
reported pain on swallowing and had fever. A rupture of the left piriform sinus was confirmed 
on a barium swallow radiograph, for which the patient was admitted and given prophylactic 
antibiotics.
One patient developed pneumothorax after EUS-FNA of a mediastinal node (yielding 
undifferentiated non-small cell lung carcinoma), requiring pleural drainage.
A mid-esophageal ulcer was reported in a patient after EUS-FNA of a subcarinal node. The 
first days after EUS-FNA he had self-limiting abdominal pains, but a few days later symptoms 
of dysphagia developed, and gastroscopy confirmed an ulcer at the puncture site. The patient 
recovered completely after antibiotic treatment.
table 4. EBUS-TBNA stratified for indications and type and graded according to the severity scale (Table 1)
Adverse event Intervention after eBus grade
1 Mediastinal abscess Thoracotomy, antibiotics 4
2 Bleeding (150 cc) Self-limiting, 4 hours clinical observation 2
3 Midazolam intoxication Full recovery following anexate 2
All indications for EBUS were non-small cell lung carcinoma.




In this nationwide, retrospective survey spanning a 12-year period in the Netherlands, we found 
that the rate of endosonography-associated SAEs for mediastinal analysis was low (0.15%), but 
with a few fatal outcomes (0.04%). SAEs were mostly of infectious origin.
In 4 cases, endosonography was judged as the primary cause of death because death occurred 
shortly after the diagnostic investigation; in 3 patients endosonography contributed to the fatal 
outcome.
In medical literature, reports of fatal outcomes after endosonography for mediastinal and/or 
pulmonary indications are rare, and the 3 cases documented were not described in detail.15,16 
Conventional bronchoscopy is seldom associated with fatal outcomes (0.004%), as shown 
recently by Asano et al18 in a large Japanese nationwide survey (N = 103,978). Results for 
TBNA-associated infections in this report were comparable with our results (0.09% vs 0.10%). 
An all-cause SAE rate of bronchoscopy including TBNA was higher than in our endosonog-
raphy survey (0.53% vs 0.15%) and was primarily caused by hemorrhage (0.28%), pneu-
mothorax (0.07%), and asthma (0.06%). Therefore, it might be concluded that US-guided 
nodal sampling is safer than “blind” TBNA. Both surveys were retrospective, however, with 
associated limitations, and therefore no firm conclusions regarding safety of US-guided versus 
blind TBNA can be made.
The fatalities described in this article mostly were in patients of frail health and poor perfor-
mance status (all American Society of Anesthesiologists Physical Status Classification System 
score III or IV). Four of 7 patients had tissue-proven locally advanced (stage III A-B) lung 
cancer, 1 had distant metastatic non-small cell lung carcinoma (stage IV), and 2 patients were 
highly suspected of having locally advanced central lung cancer. However, 1 patient had no 
significant medical history, in 1 patient only one comorbidity, diabetes, was known, but the 4 
other patients had considerable comorbidities including COPD (GOLD grade III to IV) (N 
= 3), serious aortic valve stenosis and regurgitation, and obstructive sleep apnea, and 1 patient 
had a recent cardiopulmonary arrest.
The reason we found endosonography-related fatal outcomes could be that adverse events 
outside study settings were included. Second, publication bias may have contributed to the 
absence of reported mortality.
Regarding the SAEs, most patients presented with an infectious adverse event. This is in line 
with the medical literature in which infectious adverse events are most prevalent in addition 
to hemorrhagic events and perforations8,16 Part of the infectious SAEs in cysts and sarcoidosis 
(Table 2) have been reported in case reports. However, in this review almost half of the patients 
with an infectious SAE were lung cancer patients, suggesting that these infections can be 
expected in all patients undergoing endosonography, independent of the final diagnosis.
In the patients with infectious adverse events, various different pathogens were cultured, and 
no specific virulent pathogen could be identified. Nevertheless, most cultured species are com-
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mon residents of the (upper) GI tract, and the involved patients had no apparent risk factors 
for decreased host-immune response. It might be that these adverse events occur because of 
iatrogenic inoculation of the mediastinal area by oropharyngeal flora, introduced by the needle 
through the working channel of the endoscope. Needle contamination is probably common. In 
a small, single-center study, TBNA needle washing cultures were positive in 35% of patients, 
leading to bacteremia without clinical signs of infection in 7% of patients.19
Cases of damage to the GI tract after EUS (including pneumomediastinum) were rare in 
our cohort (N = 7, 0.05%) and are in line with the incidence of such adverse events in EGDs 
in medical literature (0.03%).20 Considering the normal use of EGDs, it seems that use of the 
sheet and needle is safely performed in general and only incidentally leads to tearing of the 
esophageal wall.
The present study offers some strong points. It was a 12-year survey of all EUS-FNA and 
EBUS procedures in all hospitals in the Netherlands (both local community hospitals and ex-
pert centers) and with skilled teaching physicians as well as beginners. This adds to the external 
validity of the study and gives a more reliable interpretation of endosonography-associated 
adverse events in daily practice. Second, because we also sent out questionnaires to those clinics 
that referred patients for endosonography, we were able to include late adverse events that 
otherwise might have been lost.
Several limitations apply to the study. First, because of the retrospective nature, recall bias 
applies, and therefore SAEs may have been missed. Data are partly based on available local 
adverse event registers and on the memory of individual physicians. Also, mortality and SAE 
rates may vary slightly from the actual rate because our rates represent an estimation of the 
performed procedures in each center and not the actual rate. Furthermore, the amount of 
depicted EUS-FNA procedures considerably exceeds the number of EBUS procedures, which 
reflects the 1999 to 2011 period in the Netherlands. To date, more EBUS procedures or 
combined EBUS and EUS-B (transesophageal mediastinal sampling using the EBUS scope) 
are performed.
Also, a lack of accurate follow-up may have excluded adverse events not immediately ap-
parent after endosonography. Infections that have been attributed to procedures such as me-
diastinoscopy or thoracotomy may have occurred, which are often performed after a negative 
EUS-FNA or EBUS procedure.
Which lessons may be derived from these data? Principally, as for any procedure, it is crucial 
that there exists a clear indication for endosonography. Fatal outcomes are rare but do occur 
incidentally and are strongly associated with poor performance status and/or comorbidities. 
The risk of SAEs after endosonography mainly includes mediastinitis and/or mediastinal 
abscess formation. Patients with granulomatous disease and necrotic nodes seem to be at risk.
As always, investigators should be aware of developing adverse events, and patients should 
be instructed to report minor complaints such as fever, coughing, and thoracic or abdominal 
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EUS-FNA has been reported to be a safe and accurate diagnostic method for investigating 
mediastinal lymph nodes (LNs) in patients with suspected lung cancer and sarcoidosis.
The safety record of EUS-FNA in patients with mediastinal tuberculosis (TB) is unknown. 
We describe a patient with TB who developed mediastinal-esophageal fistulae after EUS-FNA 
of a tuberculous subcarinal LN.
CAse rePort
A 26-year-old man from India who lived in Northern Europe for 3 years presented with symp-
toms of weight loss (5 kg) and mediastinal lymphadenopathy (Fig. 1). He
reported no cough, fever, or night sweats. Travel and family history were negative for TB. 
EUS-FNA of the subcarinal LN was performed based on the clinical suspicion of TB to obtain 
both a tissue diagnosis and material for TB culture.
With the patient under conscious sedation with midazolam, EUS was performed with a 
Pentax FG-34UXecho-endoscope (Pentax, Hamburg, Germany) attached to a Hitachi EUB-
6500 US scanner (Hitachi, Reeuwijk, The Netherlands).
On EUS, between the esophagus, left atrium, and pulmonary artery (station 7) (Fig. 2), an 
inhomogeneous and sharply demarcated subcarinal mass was seen with a maximum diameter 
of 25 mm. Four FNAs were performed using a 22-gauge needle with suction (GIP/MEDI-
Globe, type Hancke/Vilmann).
After the procedure, the patient was observed for 1.5 hours and was discharged without any 
symptoms.
figure 1. CT scan of the chest per-
formed before EUS-FNA demon-
strating enlarged subcarinal lymph 
nodes (LN). ES, Esophagus.
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Cytological smears and tissue block of the aspirated material revealed granulomas with ne-
crosis (Fig. 3). The results of Ziehl-Neelsen auramine staining and polymerase chain reaction 
for Mycobacterium tuberculosis were all negative.
Two days after the procedure, the patient noticed pain when swallowing. Thereafter, the 
symptoms spontaneously subsided, but returned after 7 days accompanied by coughing. A 
CT-scan revealed extensive mucosal swelling of the esophagus as well as multiple submucosal 
air collections (Fig. 4).
On gastroscopy, 3 mucosal lesions, each with erosive features and a circular ulcer, were noted 
in the esophagus 25 to 30 cm from the incisors (Fig. 5), the largest 2 of which discharged 
puslike material that was obtained and was positive for M tuberculosis (normally sensitive) 
after several weeks.
figure 3. Cell block of cytological 
material of an EUS-FNA aspirate 
demonstrating a granuloma (G) with 
necrosis (N). LT, Lymphoid tissue.
figure 2. Linear EUS echo-image 
demonstrating enlarged and inho-
mogeneous subcarinal lymph nodes 
(LN), located below the main ca-
rina of the airways and between the 
esophagus (ES), left atrium (LA), 
and pulmonary artery (PA).
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Under the clinical diagnosis of mediastinal TB with esophageal-mediastinal fistulae, tubercu-
lostatic medication was started. The patient recovered quickly, infection parameters decreased, 
and shortly after the initiation of the treatment, the patient was symptom free. Three months 
later, CT revealed that the fistulae openings had completely re-epithelialized (Fig. 6), and the 
mediastinal air collections had significantly decreased.
figure 4. CT scan of the chest performed 15 
days after EUS-FNA of the subcarinal lymph 
nodes. Air collections (A) are visible within 
the subcarinal lymph node.
figure 5. Gastroscopic image of the esopha-
geal mucosa (25-30 cm from the incisors) 
demonstrating a mediastinal-esophageal fis-
tula (MEF).
figure 6. Gastroscopic image of the esopha-
geal mucosa after 3 months of tuberculostatic 





We report the occurrence of multiple mediastinal-esophageal fistulae after EUS-FNA of medi-
astinal LNs with TB.
Patients with TB often present with mediastinal lymphadenopathy. The esophagus itself is 
rarely affected by TB.1 Although spontaneous fistulae formation of mediastinal LNs with TB 
of the esophagus can occur,2 in our opinion, it was an adverse event of EUS-FNA in this case. 
Esophageal-mediastinal fistulae often present with localized mediastinal gas collections,3 as 
observed in the case described here.
EUS-FNA appears to be a very safe technique for the aspiration of LNs and masses in the 
mediastinum in patients with lung cancer and sarcoidosis.4-6 Mediastinitis has been described 
as a rare complication after EUS-FNA of cysts7,8 and necrotic LNs.9
To date, very few data exist concerning the yield and safety of EUS-FNA for the analysis of 
mediastinal TB. No complications were described in 2 small series10,11 with, respectively, 2 and 
8 patients with mediastinal TB.
Although in our case the fistulae occurred after EUS-FNA of mediastinal LNs in a patient 
with TB, generally the risk factors for the development of mediastinal fistulae are not entirely 
clear and likely not limited to infections. Nevertheless, with regard to the high prevalence of 
TB and the rapid implementation of EUS-FNA for the diagnosis of mediastinal lesions, we 
believe that endosonographers should be aware that EUS-FNA of necrotic tuberculous LNs 
can induce mediastinal fistulae. Further data are needed to determine the yield and safety of 
EUS-FNA for mediastinal TB.
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Obtaining tissue from a para-aortal lymph node or tumor is a challenge that currently requires 
invasive surgical procedures. Para-aortic lung tumors can be clearly visualized by EUS. Al-
though the accessibilityof lesions adjacent to the esophagus is well documented, the para-aortic 
region has never been systematically explored.
Objective
To assess the feasibility, yield, and safety of transaortic biopsy specimens in the diagnosis of 
lung tumors and nodal masses located lateral to the aorta.
Design
A retrospective case series of 14 consecutive patients.
Setting
Pulmonary Department, Leiden University Medical Center, Leiden, The Netherlands.
Patients
Fourteen patients with known or suspected lung cancer. Nine patients presented with a left-
sided lung mass (mean size 27 mm), whereas 5 patients had an enlarged para-aortic node 
(mean size 16 mm).
Interventions
Real-time EUS-guided transaortic biopsy of a para-aortic lesion.
Main outcome measurements
Feasibility, diagnostic yield, and complication rates of transaortic EUS-guided FNA (EUS-
FNA).
Results
The final diagnosis was known in 12 patients (10 non-small-cell lung carcinoma [NSCLC], 1 
small-cell lung carcinoma [SCLC], and 1 renal-cell carcinoma). EUS-FNA established malig-
nancy in 9 of 14 patients (64%) (8 NSCLC and 1 SCLC). One aspirate revealed reactive nodal 
tissue, and 4 demonstrated non representative material.
Malignancy was further assessed in 3 patients after subsequent diagnostics. Transaortic FNA 
was found to be safe. In 2 patients, EUS images after biopsy were suspicious for a small para-
aortic hematoma. These patients recovered uneventfully.
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Conclusions
These results demonstrate that a single EUS-guided transaortic biopsy of para-aortic lymph 





Obtaining a tissue diagnosis from a lung tumor or a mediastinal lymph node located lateral 
to the aorta traditionally has been regarded as a diagnostic challenge because of the interposi-
tion of the aorta. Surgery (mediastinotomy, thoracotomy, or video-assisted thoracic surgery 
[VATS]) is frequently required for the diagnosis of these lesions.1,2
However, these procedures are invasive and costly and require hospital admittance.
Tumors and mediastinal lymph nodes located in the para-aortic region can easily be identi-
fied by esophageal EUS, because the aorta provides an excellent medium to transfer US waves 
(Fig. 1). 
Paraesophageal lymph nodes and centrally located intrapulmonary tumors can accurately 
be aspirated by using EUS-guided FNA (EUS-FNA).3,4 To date, it is unknown whether it is 
feasible and safe to biopsy intrapulmonary lung tumors and mediastinal lymph nodes through 
the aorta with EUS-FNA. Therefore, we aimed to evaluate the feasibility, yield, and safety of 
EUS-guided transaortic FNA of lung tumors and para-aortic lymph nodes.
figure 1. EUS image from the esophagus (OE), demonstrating lymph node station 6 (LN) located lateral to the 
aorta (AO). Doppler flow (DP) is seen in the aorta.
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PAtIents And methods
Fourteen consecutive patients with suspected (n = 13) or proven malignancy (n = 1) who un-
derwent transaortic FNA of a mass located adjacent to the aorta were retrospectively included 
in this case series between April 2003 and April 2008. Informed consent was obtained in all 
cases, and, in all cases, the para-aortal lesion was the only site suspicious for malignancy (Fig. 
2). Based on the available CT and positron emission tomography (PET) imaging, a trans-
esophageal biopsy of the lesion performed through the aorta was regarded as the only option to 
diagnose or stage these patients by means of a minimally invasive procedure.
In the majority of the cases, the lesion punctured under echo guidance was a suspected 
primary lung tumor situated lateral to the aorta (4 left lower lobe, 4 left upper lobe, 1 lingula). 
One patient presented with a para-aortic mass suspicious for a metastasis from a renal-cell 
carcinoma. The remaining 5 patients underwent transaortic FNA for an enlarged para-aortic 
mediastinal lymph node (mean size on CT 16 mm, range 10-20 mm), suspicious for N2 
disease (node 6, n = 3; node 5, n = 2).
EUS-FNA procedures were performed at the Department of Pulmonary Medicine of the 
Leiden University Medical Center (LUMC) by 2 experienced investigators (J.T.A., K.F.R.) 
on an outpatient basis with the patient under moderate sedation with midazolam (0-5 mg 
intravenously). The LUMC is a tertiary-care hospital, and the pulmonary department is a 
figure 2. CT image, demonstrating a para-aortic lung tumor (TU). OE, esophagus; AO, aorta.
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referral center for the analysis of mediastinal lesions by EUS-FNA. Investigations were per-
formed by using a Pentax FG 34 UX echo-endoscope (Pentax, Breda, The Netherlands), with a 
longitudinal convex US transducer that had an adjustable US frequency of 5, 7.5, or 10 MHz, 
in combination with a Hitachi EUB 6500 US scanner (Hitachi Ultrasound, Reeuwijk, The 
Netherlands). All aspirates were obtained under real-time USguided FNA by using a 22-gauge 
needle (type Hancke/Vilmann; GIP/MEDI-Globe, Achenmühle, Germany).
During the EUS procedure, the investigators first systematically assessed all mediastinal 
nodal stations detectable from the esophagus. When no suspicious lesion was seen other than 
the mass in the para-aortic region, Doppler flow was applied to distinguish the lung mass or 
node from the aorta (Fig. 1). Before any transaortic FNA, we first tried to mobilize the esopha-
gus, by deflecting the tip of the endoscope, to try to position the EUS endoscope immediately 
adjacent to the target lesion. In case the transaortic route was the only option, a single real-time 
biopsy of the lung mass or lymph node was performed in the absence of intraluminal aortic 
plaques. Vacuum suction was applied as soon as the tip of the needle
reached the target lesion. After retracting the needle, the para-aortal area was observed on 
echo images for 3 minutes to assess for immediate procedure-related complications, and the 
aspirate was put on both glass slides, as well as in a fixative for cell block evaluation. One of 
figure 3. Real-time EUS-guided transaortic aspiration of a para-aortic lymph node (LN). The needle (ND) is well 
visible within the aorta. OE, esophagus; AO, aorta.
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the endoscopists evaluated the representativity of the aspirates during the procedure by using 
on-site cytology.
The applied criterion standard for the involvement of malignancy in the target lesion was 
determined either by the presence of malignant cells in the cytologic material obtained by 
EUS-guided transaortic FNA or by subsequent surgical-pathologic confirmation of the para-
aortic lesion. False-positive EUS aspirates were considered highly unlikely.
results
In all 14 patients, real-time visualization of the needle through the aorta into the target le-
sion was achieved (Fig. 3), and aspirates were obtained in all subjects. Patient characteristics, 
EUS-FNA findings, and follow-up are presented in Table 1. A single transaortic FNA was 
confirmative for malignancy in 9 patients (64%). Seven of those patients had a suspected pri-
mary lung tumor, and aspirates of those tumors revealed large-cell undifferentiated carcinoma 
(n= 5), adenocarcinoma (n = 1), and small-cell lung carcinoma (n = 1). The other 2 patients in 
whom EUS-FNA found malignancy had a mediastinal para-aortic lymph node and aspirates 
that showed large-cell undifferentiated carcinoma in both cases. For the 5 patients in whom 
transaortic EUS-FNA did not find malignancy in the para-aortic lesion, biopsy specimens 
table 1. Patient characteristics, EUS-FNA findings, and follow-up
Case no. sex/
Age(y)
mass eus cytology of mass short-axis of mass final diagnosis of the mass
1 F/52 LLL NSCLC 20mm NSCLC*
2 M/77 Node 6 Reactive nodal tissue 10mm NSCLC+
3 F/49 LUL Adenocarcinoma 20mm Adenocarcinoma+
4 M/72 Node 6 Erythrocytes 20mm Information not available 
5 F/66 Node 5 NSCLC 15mm NSCLC*
6 M/75 LUL NSCLC 46mm NSCLC*
7 M/71 LLL NSCLC 40mm Squamous carcinoma+
8 F/51 LLL Lytic material 26mm Adenocarcinoma+
9 F/65 LUL SCLC 13mm SCLC*
10 F/52 Node 6 Squamous epithelial cells 14mm Information not available
11 F/63 LLL NSCLC 35mm Adenocarcinoma+
12 F/49 LUL Erythrocytes 15mm Renal cell carcinoma+
13 F/51 Lingula NSCLC 25mm NSCLC* 
14 M/57 Node 5 NSCLC 20mm NSCLC* 
LLL, Left lower lobe; LUL, left upper lobe.
*Based on cytology EUS, no further surgical confirmation.
+ Confirmative surgical pathology of mass biopsied on EUS.
108
Chapter 8
disclosed erythrocytes (n = 2), reactive nodal tissue (n = 1), squamous epithelial cells from the 
esophagus (n = 1), and lytic material (n = 1). These 5 patients underwent subsequent surgical 
staging (3 thoracotomies, 1 mediastinotomy, and 1 VATS), and malignancy was found in 3 of 
the 5 patients.
In the 2 remaining cases, metastatic disease was found in a site other than the para-aortic 
area, and, therefore, no final tissue diagnosis was obtained from this lesion.
In 2 patients (Table 1, case nos. 10 and 14) a para-aortic extravasate compatible with a 
local hematoma was observed on echo images immediately after transaortic FNA. One patient 
complained of chest discomfort for a short duration, whereas the other subject remained as-
ymptomatic. The former patient was admitted overnight, and a CT was performed the next day 
to exclude aortic dissection. The CT images demonstrated a para-aortic hematoma (maximal 
short-axis diameter of 2 cm), without evidence of aortic dissection.
dIsCussIon
This case series demonstrates the feasibility of transaortic aspiration in para-aortic lesions under 
real-time controlled EUS guidance. A single EUS-guided transaortic FNA was diagnostic for 
malignancy in 64% of the patients. The yield in the current study is somewhat lower than other 
studies that assessed mediastinal node enlargement and centrally located intrapulmonary masses 
by EUS-FNA.3-5 This, however may be explained by the fact that only a single attempt at trans-
aortic FNA was made in all patients. For mediastinal nodal staging, a prospective study showed 
that, for an optimal diagnostic yield, at least 5 biopsies should be performed.6 On-site cytologic 
evaluation of the aspirate may probably increase the diagnostic yield of transaortic FNA.
Lymph nodes and tumors at the contralateral side of the aorta can be easily visualized through 
the blood interface of the vessel. However, small lymph nodes in this region (Fig. 3) are located 
quite some distance from the echo probe, which makes it sometimes difficult to find the right 
angle when inserting the biopsy needle.
To our knowledge, this is the first study of EUS-guided transaortic FNA for the diagnosis 
and staging of lung cancer. Wallace et al7 recently published a case report of 1 transaortic 
FNA, which obtained a diagnosis of lung carcinoma without complications. Nevertheless, 
the procedure of puncturing through the aorta is not a novel method. Ischia et al8 reported a 
transaortic celiac plexus block in 28 patients in 1983. In addition, translumbar aortography, 
a direct percutaneous lumbar puncture of the aorta for diagnostic arteriography of the ab-
dominal aorta, was a common procedure in the 1960s and 1970s. Postprocedure EUS images 
performed immediately after the puncture demonstrated a para-aortic hematoma in 2 patients.
In the radiology literature, it is not uncommon that small retroperitoneal hematomas de-
velop after translumbar aortography. However, clinically important bleeding only occurred in 
0.1% to 0.5% of the cases when 20-gauge needles were used.9
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In a review article of 14,550 patients who underwent translumbar aortography, the inves-
tigators documented 7 major (0.05%) and 2 fatal (0.014%) complications.10 Although this 
article suggests that the development of hematomas is not uncommon and, in general, the 
bleeding does not require clinical intervention, it still warrants caution for future EUS-guided 
transaortic biopsies, because the precise morbidity rates remain uncertain.
Whether 25-gauge needles will reduce the bleeding risk and, meanwhile, provide a similar 
diagnostic yield, is unknown.
If transaortic FNA is considered, then extra caution should be taken when echo images show 
aortic calcifications suggestive of aortic atherosclerotic plaques. In this scenario, transaortic 
FNA could lead to the dislocation of the plaque, which results in embolism of small arteries.
The latter may cause a ‘‘blue toe syndrome’’11 but may also result in more severe complications, 
such as subacute renal failure and intestinal ischemia.12 In addition, it is unknown whether 
hematogenous tumor seeding can occur if a lesion is biopsied through a vessel. Therefore, the 
number of needle passes should be reduced to the minimum.
Another hypothetical risk is the laceration of the aortic wall that results in aortic dissection. 
Para-aortic lung tumors and lymph nodes can also be diagnosed by parasternal mediastinoto-
mies or by a left-sided VATS. Mediastinotomy, also known as the Chamberlain method, is 
considered to be a valuable technique nowadays for the evaluation of lesions in the aortopul-
monary window. Best et al13 performed a study that evaluated the yield and safety of 62 anterior 
mediastinotomies and found a sensitivity of 98% and specificity of 64.5%. The morbidity rate 
in this study was 16.1% (wound infection 6.5%, life threatening hemorrhage 3.2%, left vocal 
cord paralysis 3.2%, and atelectasis left lower lobe 1.6%), and the mortality rate was 1.6%.13
Another method to assess the para-aortal region for malignant disease is left-sided VATS. In 
a large complication study of 895 patients who underwent video-thoracoscopy for several indi-
cations (569 cases were lung operations), complication rates were as high as 14% (dysrhythmia 
6.1%, prolonged air leak 4.7%, respiratory failure, and/or pneumonia 1,8%).14 Cerfolio et al1 
performed a retrospective study on 39 patients with VATS for the analysis of N2 disease in 
the aortopulmonary window and demonstrated a sensitivity of 100%. Transaortic FNA should 
only be performed in the absence of alternative minimally invasive diagnostic procedures. The 
technique of obtaining a tissue diagnosis from a para-aortic lesion requires skill and expertise 
in performing EUS-FNA, and whether less-experienced investigators can perform a diagnostic 
transaortic FNA of a mass in the para-aortic area remains uncertain.
In conclusion, these results show that transaortic FNA is a feasible and probably safe method 
for obtaining a tissue diagnosis from a lung tumor or a mediastinal lymph node. However, 
these results should be interpreted clinically and with caution, and it is of utmost importance 
that, to agree on the indication when transaortic biopsy is considered, EUS-FNA investigators 
should find a balance between safety and diagnostic benefit, as well as between the risks and 
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This thesis deals with multiple aspects of mediastinal endosonography in pulmonary medicine: 
The role of EUS and EBUS in diagnosing sarcoidosis is discussed in Chapter 2-4 and in 
the first part of the general discussion. Chapter 5-8 focuses on the safety of mediastinal endo-
sonography for pulmonary diseases and is reviewed in the second part of the general discussion. 
PArt I: endosonogrAPhy In the dIAgnosIs of sArCoIdosIs
Background
Ever since its development, conventional bronchoscopy has been the method of choice to 
obtain granulomas in order to diagnose sarcoidosis. With bronchoscopy, transbronchial lung 
biopsies (TBLB), endobronchial biopsies (EBB) and conventional transbronchial needle aspi-
rations (cTBNA) can be performed to sample tissue in patients with sarcoidosis. The individual 
techniques are limited in their sensitivity in stage I and II sarcoidosis to detect non-caseating 
granulomas: approximately 50-60% (TBLB and cTBNA) and 30-50% (EBB); but when 
combined, sensitivities of over 80% can be reached.1 For many years, guidelines and expert 
opinions have advised to perform TBLB as well as EBB and cTBNA in patients with suspected 
stage I/II pulmonary sarcoidosis in case tissue verification of granulomas was indicated.2-4
In the past decade, endosonography has emerged as a promising diagnostic alternative. Pre-
liminary results suggested that both esophageal ultrasound with fine-needle aspiration (EUS-
FNA) and endobronchial ultrasound with transbronchial needle aspiration (EBUS-TBNA) 
were able to demonstrate disease-specific, non-caseating granulomas in 85-90% of patients. 
In addition, the rate of serious adverse events of endosonography seemed to be low. This is 
especially important since pulmonary physicians regularly refrain from taking peripheral lung 
biopsies because of associated adverse events as hemorrhage and pneumothorax.5
Though promising, the endosonographic approach had not been compared in a randomized 
fashion to the conventional bronchoscopic approach. Hence, at the start of this thesis, the 
optimal diagnostic strategy for patients with suspected sarcoidosis stage I/II was unknown.
The grAnulomA trial 
We initiated a randomized controlled clinical trial to compare endosonography (EUS and/or 
EBUS) with conventional bronchoscopy (TBLB and EBB) for the detection of non-caseating 
granulomas. We included 300 study participants suspected of stage I/II pulmonary sarcoidosis 
in 14 university and regional hospitals in 6 European countries. We choose not to combine 
conventional TBNA and TBLB, as we wanted to compare the advice of the current guideline 
(TBLB) to the emerging technique, endosonography.
The most important finding of the GRANULOMA study was that endosonography with 
aspiration of mediastinal lymph nodes resulted in greater diagnostic yield in comparison to 
conventional bronchoscopy with taking of peripheral and endobronchial lung tissue (80% vs 
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53%; P< .001). This confirmed our hypothesis of the superior diagnostic value of endosonog-
raphy of intrathoracic lymph nodes over transbronchial and endobronchial mucosal biopsies.
The results of the GRANULOMA trial supported the outcomes of previous studies. Smaller, 
retrospective research - including our own analysis in Chapter 2 - demonstrated a granuloma 
detection rate of around 85% for EUS-FNA.6-8 Two meta-analyses confirmed the value of 
EBUS-TBNA: Agarwal and colleagues (15 studies with 553 sarcoidosis patients) found an 
excellent diagnostic accuracy (79%) and Trisolini et al. (14 studies with 2097 patients of whom 
269 with sarcoidosis) detected a similar outcome with a pooled diagnostic yield of 79%.9,10 
A strong point of the second meta-analysis was that it evaluated patients with intrathoracic 
lymphadenopathy regardless of the suspected underlying etiology. So even in unselected pa-
tients, EBUS has very good test performance to diagnose sarcoidosis.
Subsequently, Tournoy investigated the value of endosonography after a non-diagnostic 
bronchoscopy. He published a well-designed prospective multi-center trial and found that 
bronchoscopy (with TBLB, EBB and/or cTBNA) only identified 45% of patients with a final 
diagnosis of sarcoidosis. Adding E(B)US to bronchoscopy increased the diagnostic yield to 
84%.11 
Two small prospective studies (n= 40 and n= 62) directly compared EBUS-TBNA to 
TBLB and found that EBUS had a considerable higher yield (85-94% vs. 31-37%, p both < 
0.001).12,13 Gupta only found a numerical difference in his randomized trial (n=130) in favor 
of EBUS (75% vs 70%; p=0.54) but EBUS-TBNA significantly performed better than cTBNA 
(48%; p=0.004) and EBB (36%; p<0.0001).14
It can be observed from above mentioned results that no individual technique surpasses a 
diagnostic yield of 80%. Naturally, it is interesting to contemplate whether combining proce-
dures may optimize detection of granulomas. We will address this issue in detail in the section 
on bronchoscopy combined with endosonography.
In the GRANULOMA trial, serious adverse events were uncommon (and distributed equally 
over the study arms) but minor adverse events occurred in the bronchoscopy group including 
pulmonary hemorrhage (>25 ml) in 1.3% and pneumothorax in 4.7%. In literature, bleedings 
and pneumothorax are usually reported in around 2-3% of patients.15-17
EUS vs. EBUS
EUS and EBUS have a different - though mostly complimentary - reach in the mediastinum. 
Enlarged lymph nodes are usually distributed diffusely in the mediastinum of sarcoidosis 
patients and physicians therefore determine the choice for either the EUS or EBUS technique 
on experience and/or local availability. 
Interestingly, we observed in the GRANULOMA trial that EUS-FNA was superior to 
EBUS-TBNA in demonstrating noncaseating granulomas (88% vs. 66%; p<0.01). Tournoy et 
al also found a similar outcome (94% vs. 56%; p=0.03)11 as did the study group of Gnass (89% 
vs 79%), albeit the numerical difference in the latter group was not significant.18
General discussion
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These results are somewhat surprising and it is not clear why endosonographic sampling 
of mediastinal nodes from the esophagus would differ from an endobronchial approach. The 
needles used in endobronchial and esophageal ultrasound are similar in size and shape. Can the 
difference in yield be explained by learning curve or skill? Mostly, investigators underperform 
when they are in the beginning of their learning curve and learning curves commonly exist 
when a technique is implemented. We observed in Chapter 6 of this thesis that EUS-FNA was 
predominantly performed between 1999-2011 but nowadays EBUS-TBNA has become the 
procedure of choice to diagnose pulmonary sarcoidosis. Naturally, it could be that it is more 
difficult to aspirate lymph nodes using EBUS-TBNA in comparison to EUS-FNA. Patients 
generally have minimal complaints of coughing with EUS-FNA and usually no desaturations 
occur. 
Advantages of EBUS over EUS include the fact that an endobronchial inspection can be 
performed for the presence of mucosal granulomas. It should further be acknowledged that 
EUS-FNA and esophageal ultrasound with an EBUS scope (EUS-B-FNA) might be related to 
a higher risk of mediastinal infections, as we discuss later in the section mediastinal infections 
in patients with sarcoidosis. 
At the moment a RCT is being undertaken in where patients are randomized between EBUS 
and EUS-B. (Clinical trial.gov identifier NCT02540694) Hopefully, results from this RCT 
will give more clarity on the difference in yield between EUS and EBUS in the diagnosis of 
sarcoidosis.
Stage I vs. stage II sarcoidosis
The classification of pulmonary sarcoidosis relies on the chest X-ray. Stage I and II (out of 
IV) are the predominantly occurring stages. Both stages have intrathoracic lymphadenopathy 
but stage II also presents with pulmonary lesions. It is thought that progression to stage II 
could involve more nodal fibrosis, possibly hampering needle puncturing and tissue revenue, 
although literature to support this hypothesis does not exist. 
Although the GRANULOMA trial was not formally powered to investigate this, we indeed 
found differences for both stages: Bronchoscopy including TBLB and EBB showed signifi-
cantly better results for stage II sarcoidosis than for stage I (66% vs. 38%, P<0.001). With 
endosonography, the granuloma detection rate was higher in stage I compared to stage II, 
but the difference was only numerical (84% vs. 77%, P=0.24). In sarcoidosis stage I, endo-
sonography was definitely superior (P<0.001) but in stage II sarcoidosis the difference was not 
statistically significant (P=0.18).
Some studies also observed superior performance of EBUS-TBNA in stage I compared to 
stage II sarcoidosis19,20 however in other articles radiological stage had no impact on diagnostic 
yield.12,21 Navani and colleagues found that bronchoscopy with TBLB has a significantly lower 
yield when investigating stage I patients vs. stage II (78% vs 12%; p=0.001).12 Neverthe-
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less, there are few data to support this and further data should elucidate on the fact whether 
performing TBLB in stage I sarcoidosis should be discouraged. 
Although it has been shown that granulomas can even be found in TBLB specimens of 
patients without or only localized pulmonary lesions on chest CT scans22, it seems that bron-
choscopy with TBLB/EBB should not be the preferred procedure for stage I sarcoidosis. 
For sarcoidosis stage II, the yield of endosonography reached only 77%. Therefore a rela-
tively high number of false-negative results exist after E(B)US in stage II sarcoidosis and those 
patients may especially benefit from a stepwise approach: They could initially undergo an E(B)
US with on-site cytology and in case no granulomas are found, proceed to bronchoscopy with 
peripheral and/or endobronchial biopsies in the same setting. This is further discussed later. 
Mediastinal infections in patients with sarcoidosis
It seems that mostly EUS – and rarely EBUS - is associated with mediastinal infections in 
immunocompetent patients with sarcoidosis. In Chapter 4 we report 5 cases of mediastinal 
infections after EUS-guided FNA in a group of 252 patients with sarcoidosis, resulting in a 
complication rate of 2%. 
Likewise, in our literature review in Chapter 5 we found that in general infectious SAE 
were most prevalent in patients with sarcoidosis undergoing EUS-FNA. In our Dutch national 
survey (Chapter 6) and other literature were four more cases of mediastinitis after EUS-FNA 
in patients with sarcoidosis.23,24 Only one case of EBUS-related mediastinal abscess formation 
has recently been published.25 
We will shed light on a hypothesis of increased mediastinal infections in patients with 
sarcoidosis undergoing EUS-FNA in the second part of the general discussion on safety of 
endosonography.
Endoscopists should be aware of this complication and we suggest that in case EUS-FNA is 
performed in a sarcoidosis patient, prophylactic antibiotics should be administered in order to 
minimize the risk of a mediastinal infection. This should also be endorsed in guidelines.
Conventional bronchoscopy in the diagnosis of sarcoidosis
Endosonography is still a relatively new and expensive procedure and the choice between the 
different endoscopic techniques depends on local expertise and equipment availability. Data on 
cost-effectiveness of endosonography vs. bronchoscopy are non-existent. Acquiring the equip-
ment for endosonography is expensive but with fewer false-negative results, endosonography 
may be more cost effective. Secondly, sarcoidosis does not always present with mediastinal/hilar 
nodal enlargement, the obvious targets of E(B)US. It is estimated that approximately 10% of 
sarcoidosis patients present with stage III and 5% with stage IV sarcoidosis.26 These advanced 
stages are characterized by pulmonary opacities or fibrosis and patients in those stages will 
probably benefit more from lung biopsy than from aspiration of mediastinal lymph nodes. 
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Worldwide, many physicians still use conventional TBNA and a bronchoalveolar lavage in 
the diagnosis of sarcoidosis. New techniques such as cryobiopsy of the peripheral lung may 
increase the yield of bronchoscopy in the search for granulomas in the advanced stages.
Conventional TBNA
A recent meta-analysis and systematic review found a pooled diagnostic yield of 62% (6-90%) 
in sarcoidosis without major complications reported in over 900 patients.15 Like TBLB the 
yield is highly dependent on the operator but also on nodal size, which is reflected by the 
high variance in reported yield. Studies comparing ultrasound-guided needle aspiration (EUS 
or EBUS) all show superior yield of E(B)US to cTBNA18,20,27 because sampling preciseness 
increases but also because additional lymph node stations – not accessible to cTBNA – are 
within reach of EBUS-TBNA.
In case endosonography is not available, cTBNA may be a safe and reasonable accurate 
alternative.
Bronchoalveolar lavage 
Bronchoalveolar lavage is a procedure that can be performed during conventional bronchos-
copy to obtain a sample of alveolar cells by introducing a small amount of fluid in a section of 
the lung. Immunological analysis of the fluid may contribute to the diagnosis of sarcoidosis. 
The most characteristic finding is an elevated CD4/CD8 ratio. 
The immunological hallmark of sarcoidosis is a CD4+ T helper (Th) 1 driven response to-
wards a yet undiscovered antigen. The T helper cells produce cytokines, which in turn induce 
cell activation, proliferation and recruitment and activated macrophages and T-cells amongst 
others eventually cause the complex process of granuloma formation.28 By lung lavage the 
predominance of CD4+ Th1 cells can be measured by calculating the ratio between CD4+ Th1 
cells and CD8+ cytotoxic cells. 
Measurement of the CD4:CD8 ratio is most frequently used in the diagnosis of sarcoidosis 
but its role is under debate. 
The GRANULOMA trial included patients with stage I and II sarcoidosis and it was ob-
served that BAL with a CD4:CD8 ratio 3.5 had a sensitivity of 54% (using flow cytometry) 
in concordance with the literature. In several papers a CD4:CD8 ratio >3.5 showed a high 
specificity of 93%-96% for sarcoidosis but sensitivity was low with 53%. It has been suggested 
that because of the high specificity of the CD4:CD8 ratio, invasive tissue sampling with associ-
ated risk of bleeding and infection may be obviated in patients with a CD4:CD8 ratio > 3,5.29 
Nevertheless only 40% of biopsy-proven sarcoidosis patients seem to have CD4:CD8 ratios > 
3,5 and with the suggested algorithm, a lot of patients will therefore have to undergo another 
procedure following a non-diagnostic BAL.30 Also, even with false-positive rates below 10% 
uncertainty remains, as some of these false-positive cases will be patients with lung cancer or 
lymphoma and tissue confirmation is likely requested by physician and/or patient. 
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Drent et al. showed that BAL analysis using variables as total cell count, percentages of 
alveolar macrophages, lymphocytes, neutrophils and eosinophils, sarcoidosis could be cor-
rectly differentiated from two other interstitial lung diseases (extrinsic allergic alveolitis and 
idiopathic pulmonary fibrosis) in 94.5% of cases.31 By combining another diagnostic value, 
the CD103/CD4:CD4 ratio (<0.2) with the CD4:CD8 ratio (>3.0) Heron et al increased the 
sensitivity to 66% (specificity 89%)32 however this was not confirmed by others.33
Despite extensive research in the diagnosis of sarcoidosis, BAL merely remains supportive in 
the assessment of sarcoidosis. It seems to be most effective in differentiating sarcoidosis (stage 
III/IV) from other interstitial lung diseases. 
The focus of our thesis was limited to stage I and II sarcoidosis (so without pulmonary 
fibrosis) and the differential diagnosis often involves tuberculosis, lymphoma and lung cancer. 
In these patients accuracy of the BAL is modest and results may only be used to support the 
diagnosis of sarcoidosis. Hopefully new research will unmask certain BAL parameters that are 
more sensitive in diagnosing stage I and II sarcoidosis which potentially may obviate tissue 
sampling. 
Cryobiopsy
Alveolar lung tissue obtained by transbronchial biopsy, as described above, often lacks suf-
ficient quality due to the limited size and the crush-effect the forceps has on the biopsied tissue. 
Whenever bronchoscopy (TBLB/BAL) and/or endosonography provides non-diagnostic 
material and a tissue diagnosis is necessitated, sometimes a surgical biopsy is necessitated. 
This may be by sampling of lung tissue by video-assisted thoracotomy (VATS) or by biopsying 
mediastinal lymph nodes by mediastinoscopy.
However the associated postoperative mortality in patients with interstitial lung diseases 
was found to be 3.6% in a large recent systematic review and meta-analysis.34 Furthermore, a 
staggering 57% of patients complain of persistent pain at 7-12 months at the biopsy site.35 In 
an attempt to search for a minimal-invasive alternative to surgical lung biopsy, transbronchial 
cryobiopsy has very recently been developed. 
Cryobiopsy freezes the tip of the cryoprobe to the area of interest. Then, when the probe is 
removed with a rapid thrust, the attached frozen specimen stays attached on the probe’s tip. 
In an early feasibility study, the median sample area on the histologic slide was 5.82 mm2 
taken by forceps, compared to 15.11 mm2 when taken by cryoprobe.36 It has been shown to be 
able to obtain a histological diagnosis in interstitial lung diseases (ILD) with yields as high as 
74-80%.37 Some studies found higher rates of serious adverse events with clinically significant 
bleeding in 21-53% or pneumothorax (12-19%)38,39 but several others found few or no major 
complications.36,40 
Larger studies should determine the yield and safety of the technique in sarcoidosis and other 
ILD but it may well be a promising alternative to transbronchial and open lung biopsy. 
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towards an optimal diagnostic strategy
Unfortunately, no single procedure assessing for granulomas in the diagnosis of pulmonary 
sarcoidosis (endosonography or bronchoscopy) reaches accuracy over 80%. This leaves a sub-
stantial number of patients without a tissue diagnosis after the first diagnostic intervention.
Combining endosonography and bronchoscopy (TBLB and/or EBB) or performing both 
EUS and EBUS may overcome this suboptimal diagnostic yield and thereby minimize the 
number of false-negative outcomes. 
In the GRANULOMA trial we did not examine this but in literature several studies did.
Naturally a note of caution should be made, as when multiple endoscope introductions are 
performed or more punctions or biopsies are undertaken, the risk of serious adverse events 
will increase accordingly. Agarwal et al showed in a systematic review and meta-analysis that 
adding TBLB to TBNA increased the diagnostic yield (from 62% to 83%) but also increased 
the number of complications from none to 3.1%.15
Bronchoscopy combined with endosonography
A recent large retrospective study was done in 653 patients undergoing sequential EBUS-TBNA 
followed by TBLB (N=180) and/or EBB (N=340). It found that the total yield increased from 
84% to 89% in case EBUS was combined with TBLB and/or EBB in comparison to EBUS alone.41 
Gupta randomized 130 patients to either cTBNA+EBB+TBLB or EBUS-TBNA+EBB+TBLB 
and found that the diagnostic yield increased from 74.5% with EBUS-TBNA alone, to 93% 
when EBB/TBLB were added. Likewise, the yield of cTBNA increased from 48% to 85.5% 
when it was combined with EBB/TBLB. (14) When EBUS-TBNA is not available, almost 
similar accuracies may therefore be obtained by performing a “full bronchoscopy” (EBB/
TBLB/cTBNA), albeit with a high number of needle passes and forceps biopsies.
As mentioned, in the study by Gupta the yield of EBUS-TBNA was significantly enhanced 
by adding TBLB (but not EBB). There are however limitations to this approach. It requires two 
sets of scopes and the patient has to undergo two rather stressful endobronchial introductions. 
Procedure time will also increase and so do costs. 
Combining EUS and EBUS
An alternative option to increase the yield in assessing granulomas would be to combine EBUS-
TBNA with EUS-B-FNA (= EUS with an EBUS scope). In our opinion, certain expertise and train-
ing is required before investigators initiate esophageal endoscopy but there are obvious advantages 
to a combined approach. It requires only one scope (minimizing switching time and requiring only 
one sterilization program) and since the techniques are complementary in their reach, virtually all 
mediastinal and hilar stations can be reached. Although lymph nodes are usually diffusely enlarged 
in the mediastinum, asymmetry does occur which could favor an esophageal over an endobronchial 
approach and vice versa. Preferably EBUS-TBNA should be performed prior to EUS-B-FNA to 
minimize the risk of airway contamination by esophageal flora. 
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So far however, there are few studies that have investigated the value of both EBUS-TBNA 
and EUS-FNA or transesophageal ultrasound with a EBUS scope (EUS-B-FNA) in patients 
with sarcoidosis.
Oki et al showed in 2013 that is feasible, safe and accurate to perform EUS-B-FNA in 
patients with sarcoidosis.42 Dhooria performed a systematic review and meta-analysis and 
found that without increasing the risk of serious complications, the additional diagnostic gain 
of EUS-B-FNA over EBUS-TBNA in the diagnosis of mediastinal adenopathy was 7.6%.43 
Gnass and collegues assessed the role of EUS and EBUS/cTBNA in a RCT and found that 
of 21 patients with negative TBNA (either EBUS or cTBNA, unfortunately not specified), 
sarcoidosis was diagnosed by EUS-FNA in 9 (43%).18 
Implementing rapid on-site cytology (ROSE)
ROSE may prevent unnecessary procedures when a step-wise diagnostic approach is under-
taken. With a positive ROSE result from EUS/EBUS or cTBNA, TBLB can be omitted. 
A well-designed prospective study (N=60) by Plit et al in 2013 showed that the accuracy 
of EBUS-TBNA with ROSE correlates well with the final pathological assessment (88% vs. 
92%) and has high interobserver agreement between cytopathologists (κ=0.91).44 Likewise, 
combining ROSE-assisted E(B)US with cryobiopsy could increment the diagnostic accuracy 
of the combined techniques to values over 90%. 
Is tissue always the issue?
Despite the fact that guidelines and expert opinions3,4 suggests that tissue confirmation is 
warranted for every patient with a suspicion of sarcoidosis (Lofgren’s disease excepted), inves-
tigators should in our opinion review every case of suspected sarcoidosis critically to decide 
whether tissue conformation is really necessary. 
In my opinion, this is important as most randomized trials selecting patients with a clinical 
and radiological suspicion of sarcoidosis turn out to have a very high prevalence of sarcoidosis 
(88-94%).14,20,42,45 This could mean that chest CT and clinical features may accurately predict 
a diagnosis of sarcoidosis without the need to proceed to tissue confirmation. 
In our GRANULOMA trial, the final diagnosis of sarcoidosis was 92% in a supposedly het-
erogeneous group of patients recruited from various physicians from 14 centers in 6 countries. 
The percentage of life-threatening diseases requiring urgent action (tuberculosis, cancer etc.) 
was only 2.5%. This is especially relevant considering the occurrence of mediastinal infections 
(2%) in patients undergoing EUS-FNA for the diagnosis of sarcoidosis.46 Obviously, it must be 
stated that our results were obtained in Western Europe and whether they also hold for regions 
with a high prevalence of for instance tuberculosis or histoplasmosis is unclear. 
Future studies are needed and they should also specifically focus on certain clinical and 
radiological predictors of sarcoidosis. Not typical features of sarcoidosis include: asymmetrical 
distribution of the lymphadenopathy, inhomogeneous aspect of the lymph nodes on CT, 
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hemoptysis or (a) larger intrapulmonary nodule(s). These features could hint of underlying 
tuberculosis, lymphoma or lung cancer. 
Confocal laser endomicroscopy
Another very interesting new development, possibly obviating tissue sampling, is called confo-
cal laser endomicroscopy (CLE). CLE enables in vivo microscopic analysis during bronchos-
copy by focusing a laser beam towards the targeted tissue; the recaptured signal is displayed as 
an “optical biopsy”.47 A case report in a patient with sarcoidosis showed exiting results as CLE 
images from the mucosa showed a picture that was – corresponding to the authors - compatible 
with the subsequent histological biopsy demonstrating non-caseating granulomas.48 Studies 
evaluating CLE – both of the alveolar compartment as well as needle based in combination 
with endosonography of mediastinal nodes - are ongoing.
Conclusion
This part of the general discussion has dealt with the role of endosonography in the diagnosis 
of sarcoidosis.
The main conclusion is that endosonography with aspiration of mediastinal lymph nodes has 
superior diagnostic yield in comparison to conventional bronchoscopy with taking of periph-
eral (TBLB) and endobronchial (EBB) tissue (80% vs 53%). Guidelines advising to perform 
bronchoscopy (including TBLB and EBB) as a first choice procedure to detect granulomas 
should be revised. In case EUS or EBUS are not available, bronchoscopy may reach comparable 
sensitivity but only if cTBNA, TBLB and EBB are all performed. This will increase procedure 
time and likely also complications because of the number of needle and forceps samples. 
Endosonography significantly outperforms bronchoscopy in stage I sarcoidosis (84% 
vs. 38%), in stage II there is only a numerical difference (77% vs 66%) and the number 
of false-negative results is larger indicating that a stepwise approach of endosonography and 
transbronchial lung biopsy may increase yield in patients with suspected stage II sarcoidosis. 
The role of bronchoalveolar lavage (BAL) in diagnosing stage I and II sarcoidosis is limited 
with a sensitivity of approximately 50% and has no apparent value in the diagnosis of stage I 
and II sarcoidosis. BAL results may be important in the assessment stage III and IV sarcoidosis 
or other interstitial lung diseases and the detection/exclusion of infections.
Combining bronchoscopy/endosonography or EUS/EBUS as well as rapid on-site cytology 
and cryobiopsy, may further optimize the diagnostic yield in patients with suspected sarcoid-
osis. The development of clinical and radiological predictors and the use of the promising 




PArt II: sAfety of endosonogrAPhy
Background
Endosonography has quickly become the diagnostic method of choice for the mediastinal 
nodal tissue sampling in patients with (suspected) lung cancer and sarcoidosis. The time span 
between introduction in the Netherlands (Leiden: EUS 1999, EBUS 2004) and dissemination 
and implementation throughout the country has been achieved within a decade. 
Most data regarding endosonography had a clear focus on diagnostic accuracy and were 
executed in expert centers. Although several (serious) adverse events were reported, little was 
known about the safety and serious adverse events in the routine clinical practice. We intended 
to determine the true complication rate of endosonography, nationwide, in both expert and 
general hospitals, with a focus on fatal outcomes and serious adverse events (SAE).
mortality of endosonography
Despite the widespread use of endosonography, fatalities following the procedure had not been 
reported 
Endosonography is most regularly performed for the diagnosis and staging of (suspected) 
lung cancer and those patients are often older and frequently have smoking related comorbidi-
ties such as pulmonary emphysema, coronary heart disease and/or heart failure. As such, these 
patients might be at increased risk of developing complications following endosonography. 
Mediastinitis following aspiration of mediastinal lymph nodes has been described and this 
life-threatening condition is associated with mortality rates up to 50%. As endosonography 
is often performed in patients with increased risk of developing complications, we wondered 
whether underreporting of SAE could exist.
We aimed to find out whether there have been fatalities associated to endosonography for the 
analysis of pulmonary indications. 
In a systematic review (Chapter 5) compromising all relevant studies between 1995 and 
2012 (16.181 patients), we found that no fatal outcomes were reported. 8 patients developed 
a mediastinal infection but all recovered completely. After this review, three reports of fatal 
outcomes following E(B)US were published, but they were not described in detail. In the 
Japanese survey of Asano death due to cerebral infarction was observed in 1 case and in a 
summary of the literature death due to bleeding and a case of rapidly progressing interstitial 
pneumonia leading to death were subsequently reported (with no references available).49,50 
To assess the SAE rate of endosonography in routine clinical practice, we initiated a nation-
wide survey to obtain data of all SAE related to endosonography in the Netherlands between 
1999-2011. ZonMW, a Dutch fund stimulating health research supported this project (project 
no. 945144071).
A questionnaire was sent out to all Dutch hospitals and we asked them to report all serious 
adverse events (SAE) that had occurred after E(B)US in their clinic in the abovementioned 
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time span. Strong points of this study were that it was a survey taking into account all Dutch 
hospitals (both community as expert centers) including both skilled investigators as well as 
novices. Also, questionnaires were not only sent out to those physicians performing the inves-
tigation, but also to their colleagues in the referral clinics in order to catch late adverse events. 
We did this because these late events would probably present themselves in the referring clinic.
7 fatalities were reported in 16.750 endosonography procedures, corresponding with a 
mortality rate of 0.04%. The patients who died were mostly of frail health. A large part had 
significant comorbidities such as COPD GOLD III-IV, severe aortic valve stenosis / regurgita-
tion and one had a recent cardiopulmonary arrest. 
Although the risk of fatal outcomes is very low, it is important to realize that there is a small 
but existing risk, especially in those with poor/compromised cardiopulmonary function. These 
patients may die in rare cases following esophageal or endobronchial endoscopy. Therefore, it 
remains essential to establish a clear indication for endosonography, obtain consent, in respect 
to the limited chance of serious complications.
severe adverse events (sAe) in endosonography
In addition to mortality rates, we investigated the rate of severe adverse events following EUS 
and EBUS in pulmonary medicine. In this study we did not stratify for different indications 
for performing endosonography.
In the literature review we showed that in 16.181 patients in 190 studies, a total of 23 SAE 
occurred, resulting in a morbidity rate of 0.14% (Chapter 5).51 Interestingly enough, this rate 
was almost identical in the Dutch nationwide survey (0.15%) (Chapter 6).52 The number of 
procedures in our survey was based on retrospective recall, which may have underestimated the 
rate of SAE. At least 3 cases (mediastinitis, pulmonary embolism and bleeding >50 ml) were 
remembered but the individual case records could not be retrieved. Nevertheless, considering 
the strong design of this survey, we argue that the chance of missed complications is minimal 
and this figure probably approaches the actual rate of SAE of endosonography. 
When the complication rate of EBUS and EBUS are compared to conventional bronchos-
copy and esophagogastroduodenoscopy, they appear to be safe. 
Flexible bronchoscopy had a major complication risk of 0.53% in a large review of 4.273 
procedures53 which is larger than the EBUS figure (0.11%), but this study also included trans-
bronchial biopsy. TBLB often causes pneumothorax and pulmonary hemorrhage and these 
two complications made up for almost half of that rate. The other bronchoscopy complications 
were mostly respiratory failure cases (0.2%), which are rarely reported in EBUS cases. 
The rate of severe damage to the gastrointestinal tract caused by EUS (including perfora-
tions and pneumomediastinum) in our review (0.07%) and survey (0.05%) matches that of 
esophagogastroduodenoscopy (0.03%).54 
In our literature review, SAE were more reported in EUS (0.30%) compared to EBUS 
patients (0.05%), even though the number of EBUS procedures exceeded that of EUS (9.119 
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vs 6.042). (55) In the Dutch survey (14.075 EUS cases, 2675 EBUS) there was also a small 
difference between EUS (0.16%) and EBUS (0.11%).52 
Could it be that EBUS is the safer procedure of the two? Some complications indeed seem to 
be mainly associated with EUS. There were 4 perforations of the gastrointestinal tract follow-
ing EUS (0.07%). Also Ceuterinck et al recently described 2 cases of esophageal wall rupture 
after EUS-FNA.56 
Tearing of the large airways does not happen easily with EBUS-TBNA because of its strong 
cartilage structure. Also, in both the literature review as in the Dutch survey there were several 
patients who developed mediastinal infections in patients with sarcoidosis. This is something 
that seems to occur incidentally with esophageal, but not endobronchial sampling, as we 
showed in Chapter 4 and will discuss in the section below on mediastinal infections. In addi-
tion, it is possible that there are more EUS-FNA complications simply because the technique 
has been discovered earlier. Most pulmonary physicians use EBUS nowadays, although exact 
figures are lacking. 
Mediastinal infections 
Patients with sarcoidosis, cysts and those with necrotic lymph nodes in lung cancer and 
tuberculosis seem to be at increased risk of developing mediastinal infections as infectious 
complications occurred most in these groups of patients.51,52 Sarcoidosis patients may be at 
a relatively high risk of mediastinitis or mediastinal abscess formation (in up to 2%) when 
undergoing EUS-FNA (Chapter 4).46 
Only incidental reports of mediastinal infections have been reported in relation to the diag-
nosis and staging of non-small cell lung cancer, the main indication for E(B)US.51,52 
For cysts and necrosis it is perhaps easy to recognize why introduction of bacteria by the needle 
may lead to uncontrolled growth of bacteria. Cysts and necrosis are notably avascular and the 
host immune system has probably difficulty reaching the inoculated pathogens. Furthermore, 
contiguous endobronchial displacement of tuberculous lymphadenitic inflammation may lead 
to formation of fistula and endobronchial polyps. (57-59) It is wise to minimize the number of 
needle aspirations when tuberculosis is suspected and preferably use ROSE. 
For patients with sarcoidosis there is more to wonder on how these infectious complica-
tions develop. It seems nodal sampling from mainly the esophagus – and not so often the 
airways- may result in mediastinal infections in immunocompetent patients with sarcoidosis. 
In a retrospective analysis of all sarcoidosis patients (N=252) undergoing EUS-FNA in two 
Dutch university hospitals, we reported 5 cases of mediastinal infections, resulting in a 
complication rate of 2%.46 In our literature review we found that infectious SAE were most 
prevalent in patients with sarcoidosis (and cysts) undergoing EUS-FNA55 and in our Dutch 
national survey we found another case of mediastinitis after EUS-FNA.52 Finally, after our 
review, four more cases of mediastinal infections were reported, three in EUS-FNA23,24 and one 
in EBUS-TBNA.25 The recently reported EBUS case was only the first EBUS-related case of 
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mediastinitis, although the number of EBUS sarcoidosis studies emerging in literature suggests 
that EBUS is performed more frequently. 
First, why would patients with sarcoidosis be more susceptible to mediastinal infections? 
A recent literature review showed no increased risk of opportunistic infections in sarcoidosis 
patients.60 Naturally, particular patients may be at risk such as those with an additional immu-
nological disease, those with advanced fibrosing pulmonary sarcoidosis which predisposes to 
aspergillosis60 or those who are treated with immunosuppressive agents such as corticosteroids61 
or anti-tumor necrosis factor α (TNF-α).62 However, in our survey none of this applied to 
the involved patients.52 The hypothesis of an intrinsic immunodeficiency in patients with 
sarcoidosis has been posed many times before and is called the “paradoxical immune response” 
in where an exaggerated immune response, leading to the formation of granulomas, is con-
trasted with various immune defects (for instance reflected by the anergy to the tuberculin skin 
test).63 This fuels the theory that sarcoidosis patients may be more susceptible to mediastinal 
infections. Secondly it is possible that aspirating the highly vascular lymph nodes in sarcoid 
patients may increase risk of infections when one of these vessels rupture while puncturing and 
a hematoma is formed.25 
Secondly, why does mediastinitis and mediastinal abscess formation mostly occur in sarcoid-
osis patients undergoing EUS-FNA - and not EBUS-TBNA -, when the lymph nodes are the 
same. One might hypothesize that needle contamination is less extensive with endobronchial 
ultrasound. With EBUS, the investigator does not traverse the “dirty” esophagus and he takes 
care to keep the scope away from the pharyngeal wall in order to minimize cough reflex. 
Nevertheless, Steinfort et al. found that TBNA needle washing cultures were positive in 35% of 
patients in a small single-center study with bacteremia in 7% (neither with early nor late clini-
cal signs of infection)64 which is similar to the rate of bacteremia of 6% following EUS-FNA of 
upper GI tract lesions.65,66 Unfortunately, the EUS-FNA studies did not assess the needles for 
bacteria. It could be that bacteremia in these studies resulted from micro lacerations caused by 
the scope while crossing the oropharynx or esophagus.
More studies should elucidate the curious role of EUS-FNA associated infections in sar-
coidosis patients, especially knowing EUS-FNA results in a better yield in demonstrating 
granulomas as compared to EBUS-TBNA.11,18,45 
After we implemented prophylactic antibiotics (Augmentin 1200 mg i.v, one dose) in our 
practice in patients with suspected granulomatous diseases undergoing EUS-FNA, we haven’t 
seen any mediastinal infections anymore. Although it is unlikely that a RCT regarding prophy-
lactic use of antibiotics in these specific subsets of patients will be performed, administration 
of a single dose of IV antibiotics in sarcoidosis patients should be considered to minimize the 




Obtaining a tissue diagnosis of lymph nodes in the aortopulmonary window/para–aortic 
area has always been a diagnostic challenge. The area of interest is well visualized by EUS. In 
Chapter 8 we presented a EUS feasibility and safety study in where we showed – in a small 
sample of 14 patients - that it seemed safe to sample lesions in the aortopulmonary window 
by traversing the aorta with the needle.67 In selected cases in which there is only an isolated 
para-aortic tumor or lymph node, transaortic FNA can be an alternative to surgical biopsy by 
mediastinotomy. 
In addition, several cases have also been published showing safe passage of an EBUS needle 
through the pulmonary artery in order to reach the lesion of interest.68,69 
Patient preference
Obviously, not only mortality and serious adverse events are of importance for a newly imple-
mented technique. Patient satisfaction is deservedly getting an increasing amount of attention 
worldwide, but for endosonography both patient burden and minor adverse events are rarely 
reported.
Patients undergoing EBUS can experience cough or dyspnea especially when the probe 
makes a firm contact with the endobronchial wall. Following EUS, a sore throat can occur. 
In our experience, patients prefer EUS to EBUS when the investigation occurs using con-
scious sedation by midazolam. However, in a recent paper by Oki from Japan, data suggested 
that there was no statistically significant difference in discomfort between EUS and EBUS 
under midazolam.70 EUS-FNA however was associated with comparable tolerance using a 
lower dose of sedation, a shorter procedure time and fewer oxygen desaturations. 
Propofol use for sedation during EBUS is expanding as it is an efficient procedural sedation 
agent, it can be rapidly induced and patients recover quickly from its sedative effects. Addition-
ally it can be safely administered and titrated by an anesthesiologist nurse.71 Two prospective 
trials found that hypoxemia with oxygen saturations < 90% occurred in similar rates during 
midazolam versus propofol (around 30%).72,73 Hypotension was rare, also in another trial.74 
Moreover, in a retrospective study with prospectively collected data in over 300 patients, 
EBUS-TBNA scored a higher yield when using deep sedation with propofol versus moderate 
sedation with midazolam (80% vs 66%, p<0.01), even in a shorter procedure time (36 vs 47 
minutes, p<0.01). It appears that propofol sedation during EBUS is safe, patient friendly and 
could possibly even increase the diagnostic yield. Further randomized studies should address 
the use of propofol sedation in more detail.
training 
EUS and EBUS have been implemented in guidelines for lung cancer75-77 and hopefully will 
soon also be for the diagnosis of sarcoidosis. Although an increasing number of clinics are 
adopting the technique still no consensus exists on how training programs should be structured. 
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Importantly, competency of trainees should be measured. This is important as endosonography 
is very operator-dependent. Unskillful handling may lead to increased complications and poor 
operator performance can result in both under- and overstaging. In the latter situation the 
patient is potentially denied surgery and may be “given” a poorer prognosis.78 
It was shown that competency performing EUS-FNA and EBUS-TBNA can be monitored 
using assessment tools.79,80 Substantial variation exists in the learning curves of different ap-
prentices81 and even after 50 EBUS procedures diagnostic performance continues to improve.82 
Additionally, a simulator was helpful in the training of apprentices learning EBUS-TBNA in 
where virtual-reality simulator training proved to be more effective than traditional “see-and-
do” training.79 
Recently, EBUS / EUS-B has become an official fellowship in the training program of Dutch 
pulmonologists. The European Respiratory Society has started a training and accreditation 
program for EBUS consisting of an e-learning program, a dedicated course, simulator training, 
an observation program followed by self-performance with online evaluation of several cases. 
Competence will be measured using the validated EBUS and assessment tools (EBUSAT / 
EUSAT).79,80 
Considering the operator dependency and the small risk of serious complications, we argue 
that every endosonography novice should start with simulator training. 
Conclusion
The second part of the general discussion had its focus on the safety profile of endosonography.
We aimed to assess morbidity and mortality rates of EBUS and EUS for pulmonary indica-
tions and found that both techniques are very safe. Fatalities have been described but are very 
rare with a mortality rate of 0.04% and mostly occurred in patients of fragile health. Serious 
adverse events happen occasionally (0.15%) and are mostly of infectious origin in patients 
undergoing needle aspiration of cysts, sarcoid of necrotic lymph nodes. Cysts should not be 
aspirated; in patients with sarcoidosis, tuberculosis or necrotizing lung cancer prophylactic 
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Sarcoïdose is een auto-immuun ziekte waarbij ontstekingsreacties ontstaan in vrijwel het gehele 
lichaam. De ziekte presenteert zich vaak tussen het 20e en 40e levensjaar. 
Patiënten met sarcoïdose presenteren zich veelal met gelokaliseerde klachten van gewrichts- 
of huidafwijkingen, oogontstekingen of hoesten. Vaak hebben deze patiënten ook systemische 
klachten zoals (extreme) vermoeidheid, onbegrepen koorts en/of afvallen. De mate van ver-
moeidheid is soms zo invaliderend dat deze patiënten in de ziektewet belanden en tot 25% van 
de sarcoïdose patiënten voldoet aan de criteria voor een depressie.
In het grootste deel van de patiënten ontstaan de klachten acuut, zijn ze een relatief korte 
tijd hevig aanwezig en verminderen ze daarna langzaam. Na 12-36 maanden zijn de meeste 
klachten weer verdwenen. In een kleiner deel van de patiënten ontstaan de klachten meer 
geleidelijk. Deze patiënten ontwikkelen vaker chronische of progressieve sarcoïdose, waarbij 
ernstige klachten in de longen, hart of het zenuwstelsel ontstaan door verbindweefseling en 
waarvoor zware medicijnen nodig zijn die het immuunsysteem tegengaan. 1-5% van de sarco-
idose patiënten overlijdt uiteindelijk aan de ziekte.
Waarom deze ontstekingen bij de aandoening sarcoïdose voorkomen is nog grotendeels on-
duidelijk. Aangenomen wordt dat de ziekte ontstaat door een combinatie van erfelijkheids- en 
omgevingsfactoren. In een van de meer tot de verbeelding sprekende hypothesen wordt fijnstof 
genoemd als een belangrijke bijdragende factor aangezien er een piek incidentie was van de 
ziekte in het jaar volgend op de verwoesting van het World Trade Center in New York op 11 
september 2001. 
De ontstekingsreacties in het lichaam worden gekenmerkt door het clusteren van ontste-
kingscellen waarbij zich zogenaamde granulomen vormen. Het aantonen van deze granulomen 
is een van de hoekstenen in het vaststellen van de ziekte sarcoïdose. Omdat sarcoïdose een 
systeemziekte is kunnen de granulomen voorkomen in vrijwel alle organen maar in 90% van 
de patiënten zijn de longen en/of lymfeklieren in het mediastinum aangedaan. Dit gebied 
omvat de ruimte tussen de longen waarin zich naast het hart, de luchtpijp en de slokdarm 
ook een aantal lymfeklieren bevinden. Deze lymfeklieren hebben een belangrijke rol in het 
afweersysteem en draineren onder meer afvalstoffen vanuit de longen. Omdat granulomen vaak 
aan te treffen zijn in de mediastinale lymfeklieren speelt de diagnostiek van deze lymfeklieren 
een belangrijke rol in dit proefschrift. 
Bronchoscopie - een onderzoek met beperkingen
Sinds jaar en dag wordt gebruik gemaakt van de bronchoscopie om de ziekte sarcoïdose vast te 
stellen. Met een bronchoscopie wordt in dagbehandeling met een flexibele buis in de luchtwe-
gen gekeken. Ter plekke kan weefsel afgenomen worden van het slijmvlies van de luchtwegen 
met een klein grijpertje (biopsie). Huidige internationale richtlijnen adviseren in de meeste 
gevallen om voor dit onderzoek te kiezen wanneer gedacht wordt aan sarcoïdose en er een 
indicatie is om weefsel te verkrijgen om de ziekte aan te tonen. Helaas laat de nauwkeurigheid 
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van dit onderzoek te wensen over. Bij patiënten met sarcoïdose levert de bronchoscopie slechts 
in 60% van de patiënten de ziekte-specifieke granulomen op wanneer zogenaamde perifere 
longbiopten worden genomen. In 4 op de 10 patiënten moet na dit onderzoek dus nog een 
extra ingreep gedaan worden. In sommige gevallen moet aansluitend zelfs een ingrijpende ope-
ratie gedaan worden om diagnostisch weefsel te verkrijgen. Tevens komen complicaties in de 
vorm van klaplongen en (kleine) longbloedingen relatief vaak voor bij de perifere longbiopten 
met een complicatierisico van ongeveer 6%.
Met dezelfde bronchoscopie kunnen overigens met een dunne naald ook de eerder genoemde 
lymfeklieren in het mediastinum aangeprikt worden. Op basis van CT beelden wordt vooraf 
de plaats van de punctie bepaald, welke vervolgens tijdens het onderzoek “blind” wordt aan-
geprikt. Ondanks dat complicaties bij dit onderzoek niet vaak voorkomen wordt wel vaak 
mis geprikt omdat de lymfeklieren vaak slechts enkele centimeters groot zijn. Ook met dit 
onderzoek wordt slechts in ongeveer 60% van de sarcoïdose patiënten de granulomateuze 
ontsteking aangetoond. 
endo-echografie – een nieuw alternatief
Midden jaren 90 is een alternatief voor bronchoscopie ontwikkeld, endo-echografie. Ook met 
dit onderzoek wordt met een slang in de luchtwegen gekeken maar het grote voordeel van deze 
techniek is dat op het uiteinde van de slang een echokop is bevestigd. Deze maakt het mogelijk 
om de mediastinale lymfeklieren te lokaliseren en ze echogeleid en nauwkeurig aan te prikken. 
Omdat geluidsgolven duidelijk onderscheid kunnen maken tussen de verschillende anatomi-
sche structuren is het ook mogelijk om veiliger te werken. Het onderzoek kan daarnaast niet 
alleen vanuit de luchtpijp (endobronchial ultrasound, EBUS) uitgevoerd worden, maar ook 
vanuit de slokdarm (esophageal ultrasound, EUS). Daarmee is ook een groter bereik mogelijk 
dan met de conventionele bronchoscopie.
De eerste studies naar EUS en EBUS werden gedaan in patiënten met longkanker en lieten 
veelbelovende resultaten zien. Zowel EBUS als EUS hadden met 85-90% een veel grotere 
accuratesse dan de bronchoscopie (~60%) en deze resultaten hadden er voor gezorgd dat endo-
echografie inmiddels de eerste keus techniek was geworden om lokale uitzaaiingen van long-
kanker op te sporen. 
Voor ons was het de logische vervolgstap om aan te tonen dat ook patiënten met sarcoïdose 
het best onderzocht konden worden met endo-echografie ten faveure van de bronchoscopie. 
Om een nieuw onderzoek in de kliniek te implementeren en in wereldwijde richtlijnen op te 
nemen moet zogenaamd prospectief, gerandomiseerd onderzoek uitgevoerd worden. Bij deze 
vorm van onderzoek worden twee onderzoeken met elkaar vergeleken, waarbij de toewijzing 
tot een bepaalde groep enkel wordt bepaald door het lot. Dit is essentieel om te voorkomen 
dat de uiteindelijke resultaten worden beïnvloed door selectie-effecten. Wereldwijd ontbrak 




In dit onderzoek werd endo-echografie (EBUS en EUS) vergeleken met de standaard techniek 
zoals wordt geadviseerd in de richtlijnen (bronchoscopie). Tussen 2010 en 2013 zijn onder 
onze leiding ruim 300 patiënten in 14 ziekenhuizen in 6 Europese landen geïncludeerd.
De belangrijkste bevinding van de studie was dat EBUS en EUS inderdaad superieur zijn 
in het aantonen van granulomen ten opzichte van bronchoscopie met een opbrengst van 80% 
versus 53%. Ernstige complicaties kwamen in beide onderzoeksgroepen weinig voor maar bij 
de bronchoscopie kwamen zoals verwacht kleine klaplongen en lichte longbloedingen relatief 
vaak voor.
Wij menen dat op basis van de hogere opbrengst en het geringere aantal complicaties de we-
reldwijde richtlijn voor dit soort patiënten moet worden aangepast zodat niet de bronchoscopie 
maar endo-echografie als onderzoek van keus wordt uitgevoerd. 
Overigens liet ons onderzoek zien dat EUS in een groter deel van de patiënten een diagnose 
opleverde in vergelijking met EBUS (88% vs. 66%). Een duidelijke oorzaak hiervoor konden 
wij niet aanwijzen en nader onderzoek dient uit te wijzen of deze hogere accuratesse een toe-
valsbevinding was of niet.
In gebieden die nog geen toegang tot endo-echografie hebben is de bronchoscopie een 
betrouwbaar alternatief, zeker wanneer perifere longbiopten worden gecombineerd met blinde 
naald aspiratie. Uit studies die zijn gepubliceerd na ons onderzoek blijkt dat dan een opbrengst 
van ongeveer 80% gehaald kan worden. Dit brengt uiteraard wel meer belasting voor de patiënt 
met zich mee naast hoogstwaarschijnlijk een toename in complicaties en een toename van 
kosten voor de gezondheidszorg.
Ernstige complicaties kwamen in beide armen van de GRANULOMA studie weinig voor. 
Wel zagen we zoals verwacht wel een hoog aantal kleine klaplongen (4%) en lichte longbloe-
dingen (4%) bij de bronchoscopie patiënten. 
Complicaties en veiligheid
Het tweede deel van het proefschrift richtte zich op de veiligheid van endo-echografie. On-
danks dat zowel EUS als EBUS al veelvuldig werden gebruikt in de dagelijkse praktijk was over 
het complicatiegehalte van de techniek tot recent nog nauwelijks iets bekend. De enige studies 
die het voorkomen van ernstige complicaties als primaire uitkomstmaat hadden waren klein en 
beperkt van methodologische opzet. 
Dit deel bevat twee grote studies welke als doel hadden een inschatting te maken van het wer-
kelijke risico op majeure complicaties na een E(B)US procedure in een grote groep patiënten. 
Het ene onderzoek is een systematische review van de literatuur (16.181 patiënten) naar alle 
studies die wereldwijd over EUS en EBUS gepubliceerd zijn. Het andere is retrospectief onder-
zoek (16.750 patiënten) op data verkregen uit een vragenlijst die we naar alle ziekenhuizen in 
Nederland hebben gestuurd. Hierbij is aan de artsen gevraagd om al hun complicaties van de 
afgelopen 10 jaar te rapporteren. 
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Uit beide onderzoeken bleek dat endo-echografie een erg veilig onderzoek is. Overlijden als 
gevolg van EUS of EBUS kwam voor maar was zeldzaam (7 maal in de laatste 10 jaar in Ne-
derland, risico 0.07% per procedure). Andere ernstige complicaties kwamen slechts incidenteel 
voor (risico 0.15% per procedure) en betroffen meestal infecties. Het viel met name op dat 
patiënten met sarcoïdose die een onderzoek via de slokdarm ondergingen een hoge kans (2%) 
hadden op het krijgen van een levensbedreigende mediastinale ontsteking. Mogelijk dat het uit 
voorzorg toedienen van antibiotica tijdens de ingreep dit risico sterk kan reduceren. Sinds wij 
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